final programme

Transcription

final programme

FINAL PROGRAMME
22nd
INTERNATIONAL CONGRESS ON THROMBOSIS
Acropolis
NICE
FRANCE 6-9 October 2012
www.medleague-thrombosis.org
www.thrombosis2012.org
Committees
Speakers
CONGRESS EXECUTIVE COMMITTEE
Walter Ageno Cedric Hermans
President
Jean-François Schved (Montpellier, France)
University of Insubria, Clinical and experimental
Medicine Department. Varese, Italy
Cliniques Universitaires Saint-Luc. Division of
Haematology. Bruxelles, Belgium
Pierre Albaladejo Jean Pierre Laroche
Vice-President
Jacqueline Conard (Paris, France)
Ismaïl Elalamy (Paris, France)
Françoise Dignat-George (Marseille, France)
Emile Ferrari (Nice, France)
Thomas Lecompte (Nancy, France)
Patrick Mismetti (Saint-Etienne, France)
Isabelle Quéré (Montpellier, France)
Christine Biron-Andréani (Montpellier, France)
Honorary President
Meyer-Michel Samama (Paris, France)
COUNCIL OF THE MEDITERRANEAN
LEAGUE AGAINST THROMBOEMBOLIC
DISEASES· EXECUTIVE BOARD
President
Pier M. Mannucci
Past President
Christos Liapis
General Secretary
Maria Teresa Santos
Members
Meyer-Michel Samama
Jacqueline Conard
Paolo Prandoni
David Varon
COUNTRY COUNCILLORS
I.B. Topalov (Bulgaria)
Ana Bronic (Croatia)
Andrew Nicolaides (Cyprus)
Nevine Kassim (Egypt)
Jacqueline Conard (France)
Ismaïl Elalamy (France)
Antonios Hatzizacharias (Greece)
Anthi Travlou (Greece)
Uri Seligsohn (Israel)
David Varon (Israel)
Maria Benedetta Donati (Italy)
Paolo Prandoni (Italy)
Ali Taher (Lebanon)
Cherif Abdelkhirane (Morocco)
Zoubida Tazi (Morocco)
Manuel Campos (Portugal)
Luis Manuel Cunha-Ribeiro (Portugal)
Abdul Kareem Al Momen (Saudi Arabia)
Ivo Elezovic (Serbia)
Mojca Stegnar (Slovenia)
Amparo Estellés (Spain)
Maria Teresa Santos (Spain)
Lina Badimon (Spain)
Sami Guermazi (Tunisia)
Turgut Ulutin (Turkey)
Mehmet Nejat Akar (Turkey)
Grenoble, France
Juan Ignacio Arcelus Martínez
Universidad de Granada, Surgery Department. Granada,
Spain
Jean-François Arnal
CHU, Faculté Médicine et Université de Toulouse III.
Paris, France
Lina Badimon
Cardiovascular Research Center, CSIC-ICCC. Barcelona,
Spain
Ángeles Blanco Molina
Hospital Reina Sofía, Internal Medicine Department.
Córdoba, Spain
Chantal M. Boulanger
Paris Cardiovascular Research Center, Inserm UMR970.
Paris, France
Marie-Germaine Bousser
CHU Montpellier, Vascular Medicine Department.
Montpellier, France
Grégoire Le Gal
CHRU de la Cavale Blanche, Département de medicine
interne et de pneumologie. Ottawa, Canada
Jean-Yves Le Heuzey
Hôpital Européen Georges Pompidou, Cardiologie et
Rythmologie. Paris, France
Thomas Lecompte
CHU de Nancy-Hospital de Brabois Service d’Hámtologie
Biologique. Nancy, France
Xavier Leleu
Service des maladies du sang, Hopital Huriez. Lille,
France
Mario Mandala
Department of Oncology and Haematology. Ospedali
Riuniti Bergamo, Italy
Hôpital LARIBOISIERE. Neurology Department. Paris,
France
Patrick Mismetti
Margareth Castro Ozelo
Rienk Nieuwland
University of Campinas (UNICAMP), Hematology
Department (Hemocentro UNICAMP). Campinas, Brazil
Marco Cattaneo
Università degli Studi di Milano, Dipartimento della
Salute. Milano, Italy
Jacques Chiaroni
Marseille, France
Ariel Cohen
Paris, France
Jean-Philippe Collet
Groupe Hospitalier Pitié-Salpetrierè. Paris, France
Francis Couturaud
Cavale Blanche Hospital. Internal Medicine and Chest
Diseases Department. Brest, France
Ola E. Dahl
Thrombosis Research Institute. London, UK.
Bas de Laat
Biochemitry, CARIM. Maastricht, The Netherlands
Katrien Devreese
Gent University Hospital. Coagulation Laboratory
Department. Ghent, Belgium
Christophe Dubois
Faculty of Medicine La Timone. Marseille, France
Charles T. Esmon
Howard Hughes Medical Institute/ Oklahoma Medical
Research Foundation, Coagulation Biology Laboratory.
Oklahoma, USA
Anna Falanga
Ospedali Riuniti of Bergamo, Inmmunohematology and
Trasfusion Medicine Department. Bergamo, Italy
Pierre Fontana
University Hospital Geneva. Angiology and Haemostasis
Department. Geneva, Switzerland
Bruce Furie
Harvard Medical School. Harvard, USA
Muriel Giansily-Blaizot
CHU of Montpellier (Hôpital Saint Eloi), Hématologie
Biologique Department. Montpellier, France
Augustin Hellmut
German Cancer Research Center, Vascular Oncology and
Metastasis Research Department. Heidelberg, Germany
Saint-Etienne, France
Academic Medical Centre of the University of
Amsterdam. Clinical Chemistry Department . Amsterdam,
The Netherlands
Mette Nørgaard
Aarhus University Hospital, Clinical Epidemiology
Department, Aarhus, Denmark
Vittorio Pengo
Clinica Cardiologica, Centro Trombosi. Dipartmento di
Scienze Cardiologiche Toraciche e Vascolari.Università
degli Studi di Padova, Italy
Geneviève Plu-Bureau
Paris, France
Thomas Renné
Karolinska Institute and Universitz Hospital, Molecular
Medicine and Surgerz Department. Stockholm, Sweden
Wolfram Ruf
The Scripps Research Institute. Immunology and
Microbial Science Department. La Jolla, U.S.A.
Charles Marc Samama
Cochin University Hospital. Anaesthesia and Intensive
care Department. Paris, France
Meyer Michel Samama
BIOMNIS LABORATORIES, R&D Department. Ivry, France
Stephanie Schultz
Cardiology,German Heart Center Munich, Germany
Jean-Sébastien Silvestre
Inserm U970, Paris Cardiovascular Research Center.
Paris, France
Regine Sitruk-Ware
Population Council, Center for Biomedical Research.
New York, USA
Armando Tripodi
University of Milano, Internal Medicine Department.
Milano, Italy
David Varon
Hadassah-Hebrew University Medical Center,
Hematology Department. Jerusalem, Israel
Chairmen
Ulrich Abildgaard
Amparo Estelles
Centro de Investigación Hospital Universitario La Fe
Valencia, Spain
Charles Marc Samama
Oslo University Hospital.
Oslo, Norway
Essam AboelNazar
Anne Marie Fischer
Laboratoire d’hématologie.
Hôpital Européen Georges POMPIDOU. Paris, France
Per Morten Sandset
UmQ University.
Jeddah, Saudi Arabia
Anat Aharon
Denis Gerard Wahl
Lorraine University. Nancy, France
Maria Teresa Santos
Rambam Health Care Campus. Haifa, Israel
Nejat Akar
Grigoris Gerotziafas
Cochin University Hospital.
París, France
Oslo University Hospital Rikshospitalet.
Oslo, Norway
University Hospital La Fe.
Valencia, Spain
Hôpitaux Universitaires Est Parisien, Assistance Publique
Hôpitaux de Paris. Faculté de médecine Pierre et Marie
Curie, Université Paris VI. Paris, France
Uri Seligsohn
College of Medicine & KKUH, King Saud University.
Riyadh, Saudi Arabia
Emna Gouider
Virginie Siguret Depasse
Ana Bronic
Isabelle Gouin-Thibault
TOBB-ETU Hospital.
Ankara, Turkey
Abdulkareem Almomen
Tunisia
Chaim Sheba Medical Center.
Tel Hashomer, Israel
MCU-PH, Hôpital Européen Georges Pompidou.
Paris, France
Traumatology Clinic, Clinical Hospital Centre ´Sestre
Milosrdnice´. Zagreb, Croatia
Université Paris Descartes.
Paris, France
Mojca Stegnar
Sergio Coccheri
Sami Guermazi
Hôpital Charles Nicolle de Tunis, Tunisia
Pierre Toulon
University of Bologna, Italy
Jacqueline Conard
Job Harenberg
Anthi Travlou
Hotel-Dieu. Paris, France
Ola E. Dahl
Innlandet Hospital Trust and Thrombosis Research
Institute. Kolsås, Norway
Hervé Decousus
Centre d’Investigation Clinique CIE3 (INSERM/DHOS).
Hôpital Nord CHU ST ETIENNE. Saint-Étienne, France
Francesco Dentali
Insubria University, Varese, Italy
Françoise Dignat-George
INSERM UMR 608, UFR de Pharmacie,
Campus Timone Marseille, France
Maria Benedetta Donati
Fondazione di Ricerca e Cura “Giovanni Paolo II”
CAMPOBASSO, Italy
Sabine Eichinger
Medical University of Vienna
Austria, Viena
Ismaïl Elalamy
Hôpitaux Universitaires Paris-Est. Breullet, France
Ginés Escolar
Hospital Clinic. Barcelona, Spain
Charles T. Esmon
Howard Hughes Medical Institute/ Oklahoma Medical
Research Foundation, Coagulation Biology Laboratory.
Oklahoma, USA. Clinical Pharmacology, Medical Faculty Mannheim,
University of Heidelberg Mannheim, Germany
Nevine Kassim
Ain Shams University, Faculty of Medicine.
Heliopolis, Cairo. Egypt
Silvy Laporte
MCU-PH Pharmacologie Clinique, Hôpital Nord.
Université Jean-Monnet. Saint-Etienne, France
Thomas Lecompte
Hopitaux Universitaires de Geneve.
Nancy, France
Pier M. Mannucci
IRCCS Ca’ Granda Maggiore Policlinico Hospital
Foundation. Milan, Italy
Patrick Mismetti
Hôpital Nord. Saint-Etienne, France
Pierre-Emmanuel Morange
INSERM, UMR_S 626, Université de la Méditerranée,
CHU Timone. Marseille, France
Paolo Prandoni
Clinica Medica 2, University of Padova, Italy
Meyer Michel Samama
BIOMNIS LABORATORIES.
Ivry-Sur-Seine Cedex, France
Ljubljana, Slovenia
France
Athens, Greece
Armando Tripodi
University of Milano.
Milan, Italy
Turgut Ulutin
Cerrahpasa Medical Faculty.
Instanbul, Turkey
Juana Vallés
Hospital La Fe.
Valencia, Spain
David Varon
Hadassah-Hebrew University Medical Center.
Jerusalem, Israel. Tazi Mezalek Zoubida
Ibn Sina Hospital.
Rabat, Morocco
Acknowledgements
On behalf of the Mediterranean League against Thromboembolic Diseases (MLTD), we take great pleasure in inviting you to attend the 22nd International Congress on Thrombosis in Nice (October 6-9, 2012).
Nice has been chosen for the venue of this meeting because of its location on the Mediterranean Sea,
its dynamic university and its accessibility. The Congress Centre, Acropolis, is an attractive place in
downtown Nice with a modern and functional structure.
The most important is the program of the sessions, combining both clinical and biological aspects of
thrombosis which is the aim of MLTD congresses. We have planned plenary sessions, symposia and
educational sessions on up-to-date subjects, all presented by outstanding lecturers. In addition, we trust
on your willing to send abstracts on original new findings.
New antithrombotics, antiplatelet agents and anticoagulants, are now available. Their mode of action,
indications, doses and side-effects need to be clarified, as well as their influence on laboratory tests.
In 2012, the importance of ‘old’ antithrombotics such as aspirin, clopidogrel, vitamin K antagonists and
heparins shall be considered. The guidelines have been published in different countries for a treatment
and prevention of thrombosis: they must be known and followed by clinicians in the real life.
New approaches based on cellular interactions, proteomics and genomics will be presented and discussed.
Women’s Health also is a major topic. Pregnancy, hormonal treatments for contraception, menopause
and breast cancer can increase the risk of thrombosis, and the most recent area impacts all assisted
reproductive technologies. Other innovative themes on the latest research will be developed.
We hope many of you will attend this congress and we look forward to welcoming you for a very ‘Nice’
meeting.
President
Jean-François Schved
Vice-President
Jacqueline Conard
General information
VENUE
ELECTRONIC DEVICES
Nice Acropolis (Palais des Congrès)
1, Esplanade Kennedy - BP 4083
06302 Nice Cedex 4, France
BUSINESS CENTRE
CONTINUING MEDICAL EDUCATION
This programme is accredited by the European Board for
Accreditation in Cardiology (EBAC) for 15 hours of external
CME credits. Each participant should claim only those hours
of credit that have actually been spent in the educational
activity. EBAC works according to the quality standards of
the European Accreditation Council for Continuing Medical
Education (EACCME), which is an institution of the European Union of Medical Specialists (UEMS).
In compliance with EBAC/ EACCME guidelines, all speakers/ chairpersons participating in this programme have disclosed or indicated potential conflicts of
interest, which might cause a bias in the presentations. The Organizing Committee/Course Director is responsible for ensuring that all potential conflicts
of interest relevant to the event are declared to the audience prior to the CME
activities.
BADGE
Each participant will receive a name badge upon check-in at the Registration
Desk. The badge will be considered as an official meeting document and should
be carried all the time in order to get granted access to the meeting rooms.
GALA DINNER
The Gala Dinner will take place on Hotel Palais de la Mediterranée 13,
promenade des Anglais, 06011 Nice
To attend the gala dinner, do not forget to bring your ticket or invitation. Without
it, the access to the restaurant will be denied.
The Gala Dinner will start at 20:30 hs. We kindly ask all participants for being
on time.
REGISTRATION DESK
The registration desk is located in the Main Hall in front of the entrance and it
will be open on:
Saturday October 6th 12:00 - 18:30
Sunday October 7th
07:30 - 18:30
Monday October 8th
07:30 - 18:30
Tuesday October 9th
08:00 - 15:30
PREVIEW ROOM
The preview room is located on the Hermes Foyer near the Hermes Auditorium.
All speakers should check and deliver their PowerPoint presentations to the
Preview Room at least 4 hours before the start of the session or the day before
for early morning sessions.
Sunday October 7th
07:30 - 17:00
Monday October 8th
07:30 - 18:20
Tuesday October 9th
07:30 - 14:00
CLOAKROOM - OPENING HOURS
Sunday October 7th
07:30 - 17:30
Monday October 8th
07:30 - 18:45
Tuesday October 9th
08:30 - 15:30
As a courtesy to your colleagues, we invite you to turn off or silence all electronic devices during the educational, plenary sessions and symposiums.
A Business Centre with computer facilities is available on the first floor, in the
exhibitor area.
WIFI
Internet access is available through WIFI connection in the Business Centre and
in the exhibitor area.
CATERING FACILITIES
Lunch boxes will be served in the exhibitor area, at the time specified in the
programme. Coffee breaks will be also provided during the Congress.
MEANS OF TRANSPORT
Airport
The Nice Côte d’Azur Airport is France’s second-largest international airport. It
is located 15 minutes from the Acropolis (7 km from the city centre). More than
50 airlines provide regular service to destinations throughout the world. An
80-minute flight links Nice to Paris, and is offered 23 times a day.
http://en.nice.aeroport.fr
Bus and tramway
The transport network «Ligne d’azur» proposes a single rate on the whole Urban
Community of Nice Côte d’Azur which includes 24 municipalities.
The proposed rate is fixed at 1euro both for the transport network by bus and
by tram.
Azur n°: +33 (0)810 061 006 (price local call)
www.tramway-nice.org
www.lignedazur.com
« Vélos bleus » bikes
900 bikes are available in 90 stations distributed all over the city.
Rates are established as follow:
- The first half an hour: free access (Subject to subscription)
- Between ½ an hour and 1 hour: 1 €
- Additional hour: 2 € per additional hour
Azur n°: +33 (0)810 061 006 (price local call)
Or: +33 (0)4 93 72 06 06
www.velobleu.org
Taxis
The customers have to pay only the price shown on the meter of taxis.
It is strongly recommended to the customers to require a receipt on behalf of
the taxi drivers.
Central reservations office n°: +33 (0)4 93 13 78 78
Programme at a Glance
Saturday October 6th
AUDITORIUM 1
ATHÉNA
AUDITORIUM 2
HERMÈS
12:00
Sunday October 7th
AUDITORIUM 3
RHODES
Registration
08:30-09:10
Educational Sessions
14:00-15:00 New oral anticoagulant
treatments: the role of
laboratory
Life threatening
Methology and
perioperative
statistics : How to
interprete a clinical bleeding
assay
15:30-16:30 Which antiplatelet agent
for whom?
Formation of
the clot
16:30-17:00
Circulating
biomarkers
09:10-09:45
10:00-11:00
11:00-11:30
11:30-12:40
Break
Opening ceremony
12:45-14:15
17:00-17:30 Welcome
17:30-18:15 Plenary Lecture: The
origins of mediterranean
population determined by
molecular anthropology
18:45-19:45 Concert
Soloist Bouzouki:
Nicolas Syros
Title: Canto General
Orchestra and choirs:
Les Chants de Thau
Poems: Pablo Neruda;
Music: Mikis Theodorakis
Direction: Antoine Alleman
14:15-14:45
19:50-21:00 Welcome Cocktail animated by Nicolas Syros with his musicians
Greek contemporary music
08:30-09:45 Women's health
10:00-11:00
11:00-11:30
AUDITORIUM 2
HERMÈS
Scientific Symposia
Thrombosis in
patients with
hemorrhagic
disorder
Oral Communications
Coffee Break
Plenary Sessions
11:30-12:10 Tissue factor and cancer
12:10-12:40 New insights in atrial
fibrillation
13:45-14:30
Lunch Break
14:30-15:30
Hot Topic Session 2
15:30-17:00
Oral Communications
Plenary Sessions
17:00-17:40 New insights into the
contact activation system
17:40-18:20 Angiogenesis
GALA DINNER
AUDITORIUM 3
RHODES
Unusual
thrombosis
sites
New
Anticoagulants
Break
Plenary Sessions
14:50-15:30 New oral anticoagulant
treatments in deep vein
thrombosis
15:30-16:15 New insights in atrial
fibrillation
16:20-17:50
Hot Topic Session 1
Tuesday October 9th
Monday October 8th
AUDITORIUM 1
ATHÉNA
AUDITORIUM 1
AUDITORIUM 2
ATHÉNA
HERMÈS
Plenary Sessions
Mechanisms of variability
in antiplatelet agents
response
New antiplatelet agents:
the end of resistance ?
Oral Communications
Coffee Break
Scientific Symposia
Thrombosis after surgical Thrombosis and
procedures
cancer: prevention
and treatment
Satellite Symposia
Changing landscape
in anticoagulation
– new perspectives
and treatment
strategies
(12:45-13:45)
AUDITORIUM 1
ATHÉNA
AUDITORIUM 3
RHODES
Microparticules
08:30-09:45 Antiphospholipid
antibodies
10:00-11:15
11:15-11:45
AUDITORIUM 2
HERMÈS
Scientific Symposia
Drug-induced
thrombosis
AUDITORIUM 3
RHODES
Antithrombotic
agents and
invasive
procedures
Oral Communications
Coffee Break
Plenary Sessions
11:45-12:20 What did we learn from
new oral anticoagulant
treatment?
12:20-13:00 Endothelial progenitor
cells and therapeutic
angiogenesis
14:00-15:30
Oral Communications
ROOM GALLIENI 5
POSTER SESSION
17:50-18:30 Sunday October 7th
12:45-13:45 Monday October 8th
13:00-14:00 Tuesday October 9th
Sunday October 7th
Councillors and
13:00-14:30
Foundation Meeting
Monday October 8th
12:45-13:45 General Assembly
Scientific Programme
Sunday October 7th
Saturday October 6th
12:00
Registration
14:00 - 16:30
Educational Sessions
14:00 - 15:00 First session
New oral anticoagulant treatments: the role of
laboratory (Auditorium Athéna)
Armando Tripodi
Meyer Michel Samama
Methology and statistics: How to interprete a clinical
assay (Auditorium Hermès)
Patrick Mismetti
Life threatening perioperative bleeding
(Auditorium Rhodes)
Charles Marc Samama
15:30 - 16:30 Second session
15:30-16:30
Which antiplatelet agent for whom? (Auditorium Athéna)
Ariel Cohen
Formation of the clot (Auditorium Hermès)
Bruce Furie
Circulating biomarkers (Auditorium Rhodes)
Lina Badimon
16:30-17:00
17:00-17:30
Break
Opening ceremony (Auditorium Athéna)
Welcome
Jean Francois Schved, President of the Congress
Pier M. Mannucci, President of the MLTD
Meyer Michel Samama, Honorary President of the Congress
17:30-18:15
Plenary Lecture: The origins of mediterranean population
determined by molecular anthropology
Jacques Chiaroni
18:45-19:45
Concert
Soloist Bouzouki: Nicolas Syros
Title: Canto General
Orchestra and choirs: Les Chants de Thau
Poems: Pablo Neruda;
Music: Mikis Theodorakis
Direction: Antoine Alleman
19:50-21:00
Welcome Cockatil
animated by Nicolas Syros with his musicians
Greek contemporary music
08:30-09:45
Plenary Session (Auditorium Athéna)
Chair: María Teresa Santos
08:30-09:10
Mechanisms of variability in antiplatelet agents
response
Marco Cattaneo
09:10-09:45
New antiplagents agents: the end of resistance?
Stephanie Schultz
10:00-11:00
Oral Communications (CO1, CO2, CO3)
CO1: New oral antithrombotics (Auditorium Athéna)
Chairs: Patrik Mismetti and Ola E. Dahl
C0126 VALUE-BASED PRICING FOR DABIGATRAN, RIVAROXABAN AND APIXABAN IN PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION IN GERMANY
Martin Krejczy, Svetlana Marx, Konrad Obermann, Martin
Wehling, Job Harenberg
C0131 COMPARISON OF THE EFFICACY AND SAFETY OF
DABIGATRAN, RIVAROXABAN AND APIXABAN IN
PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION USING NETWORK META-ANALYSIS
Svetlana Marx, Job Harenberg, Martin Wehling, Christel
Weiss, Hans-Christoph Diener, Victor J. Marder, Gregory
Y.H. Lip
C0227 INDIRECT COMPARISON OF THE EFFICACY AND
SAFETY OF DABIGATRAN, RIVAROXABAN AND
APIXABAN IN ELECTIVE TOTAL KNEE AND HIP REPLACEMENT SURGERY
Svetlana Marx, Christel Weiss, Martin Wehling, HannsPeter Scharf, Ola Dahl, Job Harenberg
C0295 MEASUREMENT OF DABIGATRAN AND RIVAROXABAN IN PRIMARY PREVENTION OF VENOUS
THROMBOEMBOLISM IN 106 PATIENTS, WHO HAVE
UNDERGONE MAJOR ORTHOPEDIC SURGERY. AN
OBSERVATIONAL STUDY
Samama Meyer Michel, Guinet Celine, Le Flem Lena,
Ninin Emmanuel, Debue Jean-Marc
CO2: Platelets (1) (Auditorium Hermès)
Chairs: Anthi Travlou and Mojca Stegnar
C0195 THE PRESENCE OF THE TXA2 RECEPTOR IN LIPID
RAFTS OF PLATELETS IS NECESSARY FOR PLATELET
ACTIVATION BY TXA2
Antonio Moscardó, Juana Vallés, Isabel Madrid, Ana Latorre, Ángeles Dasí, María Teresa Santos
C0188 THE ACETYLATION OF TUBULIN REGULATES DENSE
GRANULE RELEASE IN HUMAN PLATELETS
Antonio Moscardó, María Teresa Santos, Ana Latorre,
Isabel Madrid, Juana Vallés
C0343 POLYMORPHISMS OF PROTEIN TYROSINE PHOSPHATASE CD148 INFLUENCE FCGAMMARIIA-DEPENDENT PLATELET ACTIVATION AND THE RISK OF
HEPARIN-INDUCED THROMBOCYTOPENIA
Rollin Jerome, Pouplard Claire, Gratacap Marie-Pierre,
Leroux Dorothee, Aupart Michel, May Marc-Antoine, Gouilleux-Gruart Valerie, Payrastre Bernard, Gruel Yves
CO3: Fibrinogen (Auditorium Rhodes)
Chairs: Pierre Toulon and Ana Bronic
C0113 IMPACT OF DIRECT THROMBIN AND DIRECT F XA
INHIBITOR ANTICOAGULANTS ON ACL TOP FAMILY
FIBRINOGEN ASSAYS
Janet Callahan, Karen DiStasio, Denise Matte, Mary Doyle,
Mark Triscott, Philippe Lacombe
C0260 MUTATION IN FIBRINOGEN POLYMERIZATION
POCKET ASSOCIATED WITH THROMBOSIS
12:45-14:15
New Anticoagulants
Chair: Yves Gruel
Roman Kotlin, Jiri Suttnar, Kristyna Pimkova, Vera Geierova, Jan Evangelista Dyr
C0096 ASSESSING THE COMBINED EFFECTS TWO SINGLE NUCLEOTIDE GENETIC POLYMORPHISMS OF
FIBRINOGEN GENES ON THE COAGULATION CASCADE IN PATIENTS WITH STABLE ANGINA
12:45
Zoi Pallantza, Stavros Kontos, Maria Kozanitou, Stilianos
Gratsias, Athanasia Lazaraki, Maria Eleni Mplouna, Nikolaos Papageorgiou, Dimitrios Tousoulis, Antigoni Miliou,
Christodoulos Stefanadis, Zoi Pallantza
Welcome and Introduction
Yves Gruel
12:50
Pharmacology of new anticoagulants: the key
aspects
Armando D’Angelo
C0127 EVALUATION OF NEW AUTOMATIZED SOLUBLE FIBRIN/FIBRIN MONOMER METHOD
13:15
Effects of noacs on hemostasis: practical
consequences for the biologist
Carlos Aguilar
Coffee Break
13:45
Management of patients treated with noacs in emergent clinical situations
Yves Gruel
14:10
Concluding Remarks
Yves Gruel
Eli Westerlund, Jaak Eintrei, Lisbeth Söderblom, Jovan P
Antovic
11:00-11:30
11:30-12:40
Satellite Symposia (Auditorium Rhodes)
Scientific Symposia
Thrombosis after surgical procedures (Auditorium Athéna)
Chairs: Charles Marc Samama and Virginie Siguret
Asymptomatic distal DVT is not a surrogate end-point
Charles Marc Samama
Bleeding definitions in orthopaedic VTE prophylaxis
trials: a real need for standardization
Ola E. Dahl
Should we follow the 9th ACCP guidelines?
Juan Ignacio Arcelus Martínez
Thrombosis and cancer: prevention and treatment
(Auditorium Hermès)
Chairs: Ismail Elalamy and Abdulkareem Almomen
Aspirin and colorectal cancer
Christophe Dubois
Multiple myeloma: epidemiology and risk factors
Xavier Leleu
Thrombosis during myeloma: prevention and treatment
Grégoire Le Gal
13:00-14:30
14:15-14:45
Chair: Meyer Michel Samama
14:50-15:30
New oral anticoagulant treatments in deep vein
thrombosis
Pierre Fontana
15:30- 16:15 Thrombosis in hematologic malignancies
Anna Falanga
16:20-17:50
12:45-13:45
Changing landscape in
anticoagulation – new perspectives
and treatment strategies
Laporte Silvy, Mismetti Patrick, Chapelle Céline, Bertoletti Laurent, Merah Adel, Lega Jean-Christophe, Décousus
Hervé
C0346 ARE PATIENTS EXPOSED TO ANTIPSYCHOTICS TRULY AT RISK OF VENOUS THROMBOEMBOLISM?
Céline Chapelle, Sara Quenet, Xavier Delavenne, Karine
Lacut, Patrick Mismetti, Silvy Laporte, Marie-Noëlle Beyens
C0416 HIGH LIPOPROTEIN(A) AND HOMOCYSTEINE LEVELS
ARE ASSOCIATED TO THE EXTENSION OF ATHEROSCLEROTIC DISEASE IN ACUTE CORONARY SYNDROME PATIENTS.
Gabriele Cioni, Rossella Marcucci, Serafina Valente, Cristina Giglioli, Rosanna Abbate, Maria Boddi
C0419 IS PROTHROMBIN TIME A PREDICTOR OF NEW-ONSET DIABETES IN HYPERTENSIVE AND CORONARY
HEART DISEASE PATIENTS?
Gwo-Ping Jong, Tsochiang Ma
12:45 WELCOME & INTRODUCTION
Chair: Patrick Mismetti
12:50 NOVEL ANTICOAGULANTS – NEW PERSPECTIVES
IN ATRIAL FIBRILLATION
José Luis Zamorano
C0213 FIGHTING FOR ACUTE PULMONARY EMBOLISM IN
RUSSIA
13:05 CURRENT LANDSCAPE OF VENOUS THROMBOEMBOLISM – THE CLINICIAN’S VIEW
Patrick Mismetti
13:25 NEW DIRECTIONS IN VENOUS THROMBOEMBOLISM MANAGEMENT
Walter Ageno
13:35 PANEL DISCUSSION & MEETING CLOSE
All
HOT TOPICS SESSION 1 (Auditorium Hermès)
Chairs: Silvy Laporte and Sergio Coccheri
C0313 CLINICALLY RELEVANT NON-MAJOR BLEEDING: A
SURROGATE ENDPOINT FOR MAJOR BLEEDING?
VALIDATION BY META-ANALYSIS OF RANDOMIZED
CLINICAL TRIALS IN MAJOR ORTHOPEDIC SURGERY, VENOUS THROMBOEMBOLIC TREATMENT
AND ATRIAL FIBRILLATION
Cerebral venous thrombosis, pregnancy and
contraception
Marie-Germaine Bousser
Splanchnic thrombosis
Walter Ageno
Mondor disease
Jean-Pierre Laroche
Satellite Symposia (Auditorium Hermès)
BREAK
14:50-16:15
Unusual thrombosis sites (Auditorium Rhodes)
Chairs: Uri Seligsohn and Tazi Mezalek Zoubida
12:45-13:45
Councillors and Foundation Meeting (Room Gallieni 5)
Igor Bokarev, Aleksandr Medvedev
C0016 INTERNATIONAL GOOD CLINICAL PRACTICES (GCP)
GUIDELINES FOR ANTITHROMBOTICS IN CANCER
PATIENTS
D Farge-Bancel, P Debourdeau
17:50-18:30
Posters Session (PS1) (Foyer)
Monday October 8th
08:30-09:45
Scientific Symposia
08:30-09:45
Women's health (Auditorium Athéna)
Chairs: Jacqueline Conard and Per Morten Sandset
CO5: Platelets (2) (Auditorium Hermès)
Chair: Thomas Lecompte
C0166 THE RELATIONSHIP BETWEEN PLATELET GLYCOPROTEIN IIB RS5911 POLYMORPHISM AND INFLAMMATION IN COPD PATIENTS
Hilal Altinoz, Samet Ergun, Koray Ak, Zehra Oya Uyguner,
Turay Yardimci, Sermin Tetik
Estrogens and cardiovascular risk in menopausal
women: benefit or harm?
Jean-François Arnal
Estrogens, progestins, estrogenicity and new
contraceptions
Regine Sitruk-Ware
Contraception, venous thrombosis and biological
plausability
Geneviève Plu-Bureau
C0363 DISCOID PLATELET AGGREGATIONS VISUALIZED BY
IN VIVO MOLECULAR IMAGING, AND CONTRIBUTION OF INFLAMMATORY CYTOKINES
Satoshi Nishimura, Mika Nagasaki, Ryozo Nagai
C0347 THROMBIN BINDING TO PLATELETS OF YOUNG PATIENTS WITH A HISTORY OF ACUTE MYOCARDIAL
INFARCTION
Grazia Loredana Mendolicchio, Monica Bacci, Dennis
Zavalloni, Lidia Rota, Zaverio Marcello Ruggeri
Thrombosis in patients with hemorrhagic disorder
(Auditorium Hermès)
Chairs: Emma Gouider and Paolo Prandoni
C0063 DOWN REGULATION OF PLATELET ACTIVATION
MARKERS DURING LONG-TERM IMMOBILIZATION
Thrombosis during PTI
Mette Nørgaard
Thrombosis in factor VII deficiency
Muriel Giansily Blaizot
Thrombosis in haemophiliacs
Cedric Hermans
Surgery in hemophiliacs: is thromboprophylaxis
mandated?
Margareth Castro-Ozelo
Karin Arinell, Ole Fröbert, Stéphane Blanc, Anders Larsson, Kjeld Christensen
CO6: Perinatal and pediatric hemostasis (Auditorium
Rhodes)
Chairs: Nejat Akar and Pierre-Emmanuel Morange
C0160 NEONATAL THROMBOSIS: INFLUENCE OF ETHNICITY ON GENETIC RISK FACTORS
Carina Levin, M. Peniakov, C. Felszer, D. Reich, S Shalev,
Ariel Koren
Microparticules (Auditorium Rhodes)
Chairs: Françoise Dignat-George and Anat Aharon
C0240 SAFETY AND EFFICACY OF ANTICOAGULATION IN
CEREBRAL SINUS THROMBOSIS IN CHILDREN: A
SINGLE CENTER EXPERIENCE
Microparticles in vascular disorders
Rienk Niewland
Microparticles, endothelial dysfunction and
atherothrombosis
Chantal Boulanger
Microparticles, angiogenesis and cancer
David Varon
10:00-11:00
Angeles Dasi, Sara Izquierdo, Bienvenida Argiles
C0369 FACTOR V LEIDEN AND PROTHROMBIN 20210A
MUTATIONS AMONG TURKISH PEDIATRIC LEUKEMIA PATIENTS
Dilara Fatma Akin, Kadir Sipahi, Tuğba Kayaalp, Yonca
Eğin, Serpil Taşdelen, Emin Kürekçi, Üstün Ezer, Nejat Akar
C0382 THE ROLE OF THROMBOPHILIA IN THE PERINATAL
STROKE IN NEONATES: A RETROSPECTIVE STUDY
IN 54 CASES
CO4 : New oral anticoagulants (Auditorium Athéna)
Chairs: Gines Escolar and Job Harenberg
C0122 EFFECTS OF APIXABAN ON HEMOSTASIS AND REVERSAL OF ITS ANTICOAGULANT ACTION BY DIFFERENT COAGULATION FACTOR CONCENTRATES:
STUDIES IN VITRO WITH CIRCULATING HUMAN
BLOOD
Gines Escolar, Eduardo Arellano-Rodrigo, Juan Carlos
Reverter, Jaume Villalta, Victoria Veronica Sanz, Patricia
Molina, Maribel Diaz-Ricart, Ana Maria Galan
C0139 REVERSAL OF RIVAROXABAN-INDUCED PROLONGATION OF CLOTTING TIME WITH PROTHROMBIN
COMPLEX CONCENTRATE (PCC), ACTIVATED PROTHROMBIN COMPLEX CONCENTRATE (APCC) AND
RECOMBINANT FACTOR VIIA (RFVIIA) IN VITRO
Elizabeth Perzborn, Stefan Heitmeier, Volker Laux
C0190 INFLUENCE OF AGE AND RENAL FUNCTION ON THE
CONCENTRATION OF RIVAROXABAN IN PLASMA
AND URINE IN PATIENTS UNDERGOING PRIMARY
ELECTIVE TOTAL KNEE AND HIP REPLACEMENT
SURGERY
Astrid Schulze, Svetlana Marx, Christel Weiss, Job
Harenberg
C0353 UNITED KINGDOM CONSENSUS BASED PRACTICAL
GUIDE FOR THE MANAGEMENT OF HAEMORRHAGE
IN PATIENTS RECEIVING DABIGATRAN
Raza Alikhan, Rachel Rayment, Trevor Baglin, Gary Benson, Laura Green, David Keeling, Scott Marshall, Raj Patel,
Sue Pavord, Peter Rose, Campbell Tait
M. Luciani, M. Balestri, K. Girardi, L. Altomare, M. Soldati,
S. Pancotti, A. Minozzi, G. Avvisati, F. Locatelli
11:00-11:30
Coffee Break
11:30-12:40
Chair: Maria Benedetta Donati
11:30-12:10
Tissue factor and cancer
Wolfram Ruf
12:10-12:40
New insights in atrial fibrillation
Jean-Yves Le Heuzey
12:45-13:45
General Assembly (Room Galliani 5)
12:45-13:45
Posters session (PS2) (Foyer)
13:45-14:30
14:30-15:30
Lunch Break
Hot Topic Session 2 (Auditorium Hermès)
Chair: Hervé Decousus and Francesco Dentali
C0427 SYSTEMATIC REVIEW AND PATIENT-LEVEL METAANALYSIS: RESIDUAL VENOUS OBSTRUCTION TO
PREDICT RECURRENCE OF VENOUS THROMBOEMBOLISM AFTER UNPROVOKED DEEP VEIN THROMBOSIS
Marco Paolo Donadini, Walter Ageno, Benilde Cosmi,
Gregory Le Gal, Daniela Poli, Paolo Prandoni, Marco Rodger, Sergio Siracusa, Laura Young, Matteo Bonzini, Monica
Caprioli, Francesco Dentali, Alfonso Dorio, James Douketis
C0413 LACK OF ASSOCIATION BETWEEN BLOOD VISCOSITY AND THROMBOTIC EVENTS IN PATIENTS WITH
SYSTEMIC LUPUS ERYTHEMATOSUS.
C0386 A META-SYNTHESIS OF QUALITATIVE STUDIES
EXPLORING PATIENTS’ AND HEALTHCARE PROFESSIONALS VIEWS OF ATRIAL FIBRILLATION AND
ORAL ANTICOAGULANT THERAPY
A. Vayá, E. Bonet, C. Alcalá, JM. Ricart
Christian Borg Xuereb, Rachel L. Shaw, Gregory Y.H. Lip,
Deirdre A. Lane
C0060 CHRONIC OBSTRUCTIVE PULMONARY DISEASE IS
NOT ASSOCIATED WITH FUTURE RISK OF VENOUS
THROMBOEMBOLISM IN A GENERAL POPULATION
- THE TROMSØ STUDY
C0265 ELEVATED HOMOCYSTEINE LEVELS ARE ASSOCIATED WITH SYSTEMIC ATHEROSCLEROSIS IN PATIENTS WITH ACUTE CORONARY SYNDROME.
Trond Børvik, Sigrid K. Brækkan, Hasse Melbye, JohnBjarne Hansen
Gabriele Cioni, Rossella Marcucci, Elisabetta Cappellini,
Rosanna Abbate, Maria Boddi
C0250 THE APS PIEDMONT COHORT: APL PROFILE AND
RISK FACTORS FOR THROMBOTIC RECURRENCES
C0129 EFFICACY AND SAFETY OF THE NOVEL ORAL ANTICOAGULANTS IN ATRIAL FIBRILLATION: A SYSTEMATIC REVIEW AND META-ANALYSIS OF THE LITERATURE
Mario Bazzan, Antonella Vaccarino, Stefania Stella, Renato Carignola, Maria Tiziana Bertero, Barbara Montaruli,
Dario Roccatello
15:30-17:00
Francesco Dentali, Nicoletta Riva, Mark Crowther, Alexander Turpie, Gregory Lip
CO7: Antivitamin K (Auditorium Athéna)
Chairs: Armando Tripodi and Isabelle Gouin-Thibault
C0090 CAROTID ATHEROSCLEROSIS AND FUTURE RISK OF
VENOUS THROMBOEMBOLISM AND MYOCARDIAL
INFARCTION - THE TROMSØ STUDY
C0310 RISK STRATIFICATION MODELS TO PREDICT BLEEDING EVENTS IN VERY OLD PATIENTS ON VKA
TREATMENT FOR VENOUS THROMBOEMBOLISM.
RESULTS OF A PROSPECTIVE MULTICENTER STUDY
Erin Mathiesen Hald, Caroline Lind, Ellisiv Bøgeberg
Mathiesen, Tom Wilsgaard, Inger Njølstad, Sigrid Brækkan,
John-Bjarne Hansen
Daniela Poli, Emilia Antonucci, Sophie Testa, Benilde Cosmi, Gualtiero Palareti, Walter Ageno
CO9: Microparticles (Auditorium Rhodes)
Chair: David Varon and Anne Marie Fischer
C0047 PHARMACOGENETIC TESTS COULD BE HELPFUL IN
PREDICTING OF VKA MAINTENANCE DOSE IN ELDERLY PATIENTS AT TREATMENT INITIATION
C0074 INCREASED NUMBER OF CIRCULATING AND PLATELET-DERIVED MICROPARTICLES IN HUMAN BLOOD
ENHANCES THROMBOSIS ON ATHEROSCLEROTIC
PLAQUES
Mirjana Kovac, Ljiljana Rakicevic, Jelena Kusic-Tisma,
Dragica Radojkovic
Rosa Suades, Teresa Padró, Gemma Vilahur, Lina Badimon
C0323 PREDICTION MODEL OF FLUINDIONE MAINTENANCE DOSE (A NON-COUMARIN VITAMIN K
ANTAGONIST) IN THE ELDERLY INCLUDES BODYWEIGHT, AMIODARONE INTAKE, VKORC1, CYP4F2,
ABCB1 GENOTYPES BUT NOT CYP2C9 GENOTYPE
C0128 DECREASE OF MICROPARTICLES AND HEMOSTASIS
IMPROVEMENT AFTER THE TREATMENT IN HEMOPHILIA A. COINCIDENCE OR CAUSATION?
Jovan P Antovic, Fariborz Mobbarez, Danijela Mikovic,
Aleksandra Antovic
Moreau Caroline, Berndt Célia, Pautas Eric, Andro Marion,
Mahe Isabelle, Lacut Karine, Le Gal Grégoire, Duverlie
Charlotte, Lecorche Emmanuel, Gouin-Thibault Isabelle,
Golmard Jean-Louis, Loriot Marie-Anne, Siguret Virginie
C0082 CIRCULATING LEUKOCYTE- AND ENDOTHELIAL-DERIVED MICROPARTICLES SUPPORT A FIBRINOLYTIC
ACTIVITY.
C0356 EVALUATION OF INRPLUS, A PORTABLE DEVICE IN
THE MANAGEMENT OF FLUINDIONE, AN ORAL ANTICOAGULANT TREATMENT: A PROSPECTIVE CLUSTER RANDOMIZED CONTROLLED, OPEN TRIAL.
Romaric Lacroix, Laurent Plawinski, Stéphane Robert,
Loïc Doeuvre, Florence Sabatier, Sara Martinez de Lizarrondo, Anna Mezzapesa, Francine Anfosso, Aurelie S. Leroyer,
Pascale Poullin, Noémie Jourde, Sébastien M. Njock, Denis
Vivien, Chantal M. Boulanger, Eduardo Angles-Cano, Françoise Dignat-George
Pernod Gilles, Imbert Patrick, Jacquet Jean-Philippe,
Bailly Cécile, Laporte Silvy, Lièvre Michel
C0078 DOSE MODIFYING EFFECT OF VKORC1 9041G>A
AND 6009C>T GENE- POLIMORPHISMS IN ACENOCOUMAROL ANTICOAGULATED HUNGARIAN OUTPATIENTS
C0431 MICROPARTICLE TF/ TFPI HEMOSTATIC BALANCE IN
PHYSIOLOGICAL AND PATHOLOGICAL STATES
Anat Aharon, Benjamin Brenner
C0059 CIRCULATING LEVELS OF P-SELECTIN GLYCOPROTEIN LIGAND-1 (PSGL-1) POSITIVE MICROPARTICLES ARE INCREASED IN PATIENTS WITH UNPROVOKED VENOUS THROMBOEMBOLISM
Réka Mózes, Orsolya Tóth, Hajna Losonczy, Marianna
Dávid, Barbara Réger, Béla Melegh, Ágnes Nagy
C0149 LONG-TERM TREATMENT OF VENOUS THROMBOEMBOLISM, WITH MODERATE-INTENSITY VITAMIN-K ANTAGONISTS (VKA) (INR RANGE BETWEEN
1.8 - 2.5), IMPROVE PATIENT COMFORT AND DECREASES TREATMENT COSTS, WITHOUT INCREASING ADVERSE EFFECTS: A MATCHED PAIRED STUDY
17:00-18:20
Chair: Pier M. Mannucci
17:00-17:40
New insights into the contact activation system
Thomas Renné
CO8: Cardiac diseases (Auditorium Hermès)
Chair: Grigoris Gerotziafas
17:40-18:20
Angiogenesis
Augustin Hellmut
Francesc J. Casals Solé
C0316 EFFECTS OF HEMODYNAMIC FORCES ON TISSUE
FACTOR RNA EXPRESSION IN HUMAN ENDOTHELIAL CELLS
Bauer Sumpio
Manjunath Goolyam Basavaraj, John-Bjarne Hansen
GALA DINNER
Tuesday October 9th
08:30-09:45
Scientific Symposia
Antiphospholipid antibodies (Auditorium Athéna)
Chairs: Sami Guermazi and Denis Gerard Wahl
ISTH Guidelines
Vittorio Pengo
Anti beta2 glycoprotein antibodies: are they pathogen?
Bas de Laat
Antiphospholipid antibodies: evaluation of the
thrombotic risk
Katrien Devreese
Drug-induced thrombosis (Auditorium Hermès)
Chairs: Sabine Eichinger and Jacqueline Conard
Oral contraception in women with mild thrombophilia:
what we’ve learned recently?
Ángeles Blanco Molina
Adjuvant therapy for Breast cancer and thrombosis
Mario Mandala
Thrombotic risk and antipsychotics
Francis Couturaud
Antithrombotic agents and invasive procedures
(Auditorium Rhodes)
Chair: Charles Marc Samama
Cardiologist point of view
Jean-Philippe Collet
Anesthesiologist point of view
Pierre Albaladejo
Hematologist point of view
Thomas Lecompte
10:00-11:15
CO10: Deep vein thrombosis (Auditorium Athéna)
Chair: Nevine Kassim
C0170 PROPHYLAXIS OF THROMBOTIC COMPLICATIONS
IN A PREGNANT PATIENTS WITH PROSTHETIC
HEART VALVES
Alexander Makatsariya, Viktoriya Bitsadze, Dzhamilya
Khizroeva, Svetlana Akinshina, Natalya Makatsariya
C0208 PREVENTION OF VENOUS THROMBOEMBOLISM IN
ACUTELY ILL MEDICAL PATIENTS WITH RENAL IMPAIRMENT: THE FONDAIR STUDY
Walter Ageno, Nicoletta Riva, Patrizia Noris, Marcello Di
Nisio, Micaela La Regina, Dimitriy Arioli, Luigi Ria, Valter
Monzani, Stefano Cuppini, Enrico Lupia, Matteo Giorgi
Pierfranceschi, Francesco Dentali
C0302 PROGNOSTIC CLINICAL PREDICTION RULES TO
IDENTIFY LOW-RISK PULMONARY EMBOLISM: A
SYSTEMATIC REVIEW AND META-ANALYSIS
Alessandro Squizzato, Marco P Donadini, Luca Galli,
Francesco Dentali, Drahomir Aujesky, Walter Ageno
C0322 FACTORS ASSOCIATED WITH THERAPEUTIC STRATEGIES IN PATIENTS WITH SPLANCHNIC VEIN
THROMBOSIS: RESULTS OF AN INTERNATIONAL
REGISTRY
Nicoletta Riva, Walter Ageno, Sam Schulman, Soo-Mee
Bang, Maria Teresa Sartori, Elvira Grandone, Jan Beyer,
Giovanni Barillari, Dario Di Minno, Rita Duce, Alessandra
Malato, Rita Santoro, Daniela Poli, Peter Verhamme, Ida
Martinelli, Pieter Kamphuisen, Adriano Alatri, Doyeun Oh,
Elbio D’Amico, Francesco Dentali
C0383 DIAGNOSTIC ACCURACY OF LUNG ULTRASOUND
FOR PULMONARY EMBOLISM: A META-ANALYSIS
Alessandro Squizzato, Elena Rancan, Francesco Dentali,
Walter Ageno
CO11: Vascular biology (Auditorium Hermès)
Chairs: Amparo Estellés and Essam Aboelnazar
Chairmen: Amparo Estelles and Klaus T. Preissner
C0077 TISSUE FACTOR AND METALLOPROTEINASES EXPRESSION IN TWO CELL THERAPY PRODUCTS:
RELEVANCE FOR THE THROMBOGENICITY IN VASCULAR CELL THERAPY.
Tournois Claire, Cuccuini Wendy, Poitevin Gael, Pignon
Bernard, Sevestre Marie Antoinette, Nguyen Philippe
C0081 TISSUE FACTOR EXPRESSION AND MICRORNAS
–17-5P AND –20A IN ENDOMETRIAL CELL CULTURES FROM WOMEN WITH ENDOMETRIOSIS: ITS
MODULATION BY PERITONEAL FLUID
Aitana Braza-Boils, Juan Gilabert-Estellés, Luis Andrés
Ramón, Juan Gilabert Aguilar, Melitina Chirivella Casanova, Francisco España Furió, Amparo Estellés Cortés
C0080 INFLUENCE OF PERITONEAL FLUID ON MICRORNAS RELATED TO ANGIOGENESIS AND ANGIOGENIC AND FIBRINOLYTIC FACTORS EXPRESSION
IN STROMAL CELL CULTURES OF EUTOPIC ENDOMETRIA AND OVARIAN ENDOMETRIOMAS FROM
WOMEN WITH ENDOMETRIOSIS
Aitana Braza-Boils, Juan Gilabert-Estellés, Luis Andrés
Ramón, Juan Gilabert Aguilar, Melitina Chirivella Casanova, Francisco España Furió, Amparo Estellés Cortés
C0412 SOLUBLE CD146: A NEW ANGIOGENIC FACTOR INVOLVED IN PHYSIOPATHOLOGY
Karim Harhouri, Nathalie Bardin, Françoise Dignat-George,
Marcel Blot-Chabaud
CO125 IN VITRO EFFECT OF THE DIRECT XA INHIBITOR,
APIXABAN, ON GLOBAL COAGULATION LABORATORY TESTS AND COAGULATION FACTOR ASSAYS: COMPARISON OF 10 APTT AND 10 PT REAGENTS,
AND TWO COAGULOMETERS. A “GROUPE D’ETUDE
SUR L’HÉMOSTASE ET LA THROMBOSE” STUDY.
Gouin-Thibault Isabelle, Flaujac Claire, Horellou MarieHélène, Lacarrière Nicole, Lecompte Thomas
CO12: Protein C (Auditorium Rhodes)
Chairs: Charles T. Esmon and Ismaïl Elalamy
C0034 A SIMPLIFIED ASSAY FOR QUANTIFICATION OF CIRCULATING ACTIVATED PROTEIN C LEVELS
Elena Bonet, Laura Martos, Silvia Navarro, Pilar Medina,
Amparo Estelles, Francisco España
C0068 HAPLOTYPES OF THE ENDOTHELIAL PROTEIN C RECEPTOR GENE AND CIRCULATING PROTEIN C LEVELS
Laura Martos, Elena Bonet, Pilar Medina, Silvia Navarro,
Esther Zorio, Joaquín Rueda, José A. Aznar, Miguel A.
Arnau, Ana M. Osa, Amparo Estellés, Rogier M. Bertina,
Francisco España
C0069 ASSOCIATION OF HAPLOTYPES (H) 1 AND 3 OF THE
ENDOTHELIAL PROTEIN C RECEPTOR GENE (PROCR)
WITH VENOUS THROMBOEMBOLISM
Elena Bonet, Silvia Navarro, Pilar Medina, Laura Martos,
Fernando Ferrando, Amparo Vayá, Yolanda Mira, José A.
Aznar, Amparo Estellés, Rogier M. Bertina, Francisco España
C0235 IDENTIFICATION OF MUTATIONS IN THE PROTEIN C
GENE IN A PANEL OF 65 SPANISH FAMILIES WITH
PROTEIN C DEFICIENCY
Laura Martos, Silvia Navarro, Pilar Medina, Elena Bonet,
María F. López-Fernández, Vanessa Roldán, Dolors Tássies,
Pascual Marco, Ignacio Alberca, Javier Corral, Yolanda
Mira, Ramón Lecumberri, Gemma Iruin, Francisco Velasco,
Juan C. Reverter, Fernando Ferrando, María J. Costa-Pinto,
Amparo Vayá, Vicente Vicente, Ana G. Mauricio, José
R. González-Porras, Juan Monteagudo, Teresa MartínezMarini, María L. Blanco, José A. Aznar, Amparo Estellés,
Francisco España
C0076 THE ENDOTHELIAL PROTEIN C RECEPTOR IS ESSENTIAL FOR PROTEIN C ACTIVATION IN VIVO
C0094 HIGH INCIDENCE OF COMPOUND HETEROZYGOSITY IN ANTITHROMBIN DEFICIENCY: DIAGNOSTIC
AND PROGNOSTIC RELEVANCE.
Elena Bonet, Pilar Medina, Silvia Navarro, Laura Martos,
Amparo Estellés, Rogier M. Bertina, Francisco España
11:15-11:45
Sonia Aguila, Irene Martínez-Martínez, Miriam Collado,
Pilar Llamas, Antonia Miñano, Ana Isabel Antón, María Eugenia de la Morena-Barrio, Vicente Vicente, Javier Corral
Coffee Break
11:45-13:00
Chair: Françoise Dignat-George
11:45-12:20
What did we learn from new oral anticoagulant
treatment?
Charles T. Esmon
12:20-13:00
Endothelial progenitor cells and therapeutic
angiogenesis
Jean-Sébastien Silvestre
13:00-14:00
14:00-15:30
C0176 INFLUENCE OF COMMON THROMBOPHILIA POLYMORPHISMS ON THE THROMBOSIS RISK IN PATIENTS WITH JAK2-V617F-POSITIVE MYELOPROLIFERATIVE NEOPLASMS
Vangelis Giamouris, Mariana Befani, Emanouil Papadakis, Eudokia Mandala, Nikolaos Papadoulis, Spyros
Karamagiolis, Vassiliki Gastari, Eugenia Verrou, Eirini Katodritou, Stelios Lafioniatis, Zafiris Kartasis, Konstantinos
Magiannis, Paulina Marinaki, Konstantina Tsioni, Anna
Kioumi, Anastasios E. Germenis, Matthaios Speletas
C0372 ENHANCED THROMBIN GENERATION IN WOMEN
WITH HISTORY OF ORAL CONTRACEPTION RELATED VENOUS THROMBOSIS
CO13: Women’s Health (Auditorium Athéna)
Chair: Jacqueline Conard
Saša Anžej Doma, Maja Vučnik, Mojca Božič Mijovski,
Polona Peternel, Mojca Stegnar
C0284 DOES A TIGHT FIBRIN CLOT IN PREMENOPAUSAL
WOMEN WITH TYPE 1 DIABETES EXPLAIN THE
LACK OF GENDER DIFFERENCE IN CARDIOVASCULAR DISEASE?
C0430 IS THE PRESENCE OF THE MUTATION OF FXIII A KEY
OF EPIGENETIC IMPACT IN THE EXPRESSION OF
THROMBOPHILIC PREDISPOSITION?
Makris Pantelis, Pagourelias E., Makris MP., Papadopoulou AA., Giannoglou G.
Aleksandra Antovic, Nils Håkan Wallèn, Graciela Elgue,
Koteiba Majeed, Peter Henriksson, Anna Ågren, Ulf Adamson, Per-Eric Lins, Gun Jörneskog
CO15: Antiplatelets agents (Auditorium Rhodes)
Chairs: Thomas Lecompte and Juana Valles
C0298 DIFFERENTIAL RISK FACTORS FOR PREGNANCY
RELATED DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM - RESULTS FROM A POPULATIONBASED CASE-CONTROL STUDY
C0231 PATIENTS PRESENTING WITH AN ACUTE CORONARY SYNDROME WHILE ON CHRONIC ASPIRIN
TREATMENT: DO THEY REQUIRE A LOADING DOSE
OF ASPIRIN ?
Astrid Bergrem, Anders E.A. Dahm, Anne Flem Jacobsen,
Leiv Sandvik, Per Morten Sandset
Isabel Madrid, Antonio Moscardo, Juana Valles, Miguel
Ruano, Juan Bonastre, Ana Maria Latorre, Maria Teresa
Santos
C0355 PREGNANCY RELATED THROMBOSIS RISK IN PATIENTS WITH PROTEIN C DEFICIENCY
Rugeri Lucia, Khouatra Linda, Arnuti Brigitte, Trzeciak
Marie-Christine, Dargaud Yesim
C0258 IMPORTANCE OF THE EFFECT OF ASPIRIN IN PATIENTS WITH ACUTE CORONARY SYNDROME
WHO HAVE AN ADEQUATE ANTIPLATELET EFFECT
OF CLOPIDOGREL.
C0380 LONG-TERM IMPACT OF VENOUS THROMBOSIS ON
QUALITY OF LIFE, GENERAL HEALTH AND FUNCTIONING: A CROSS-SECTIONAL, CASE-CONTROL
STUDY
Isabel Madrid, Antonio Moscardo, Juana Valles, , Juan
Bonastre, Miguel Ruano, Ana Latorre, Maria Teresa Santos
Hilde Skuterud Wik, Anne Flem Jacobsen, Leiv Sandvik,
Per Morten Sandset
C0338 CORRELATION BETWEEN PLATELET FUNCTIONAL
PARAMETERS MEASURED BY IMPENDANCE AGGREGOMETRY AND BLOOD COAGULATION MARKERS WITH OCCURRENCE OF MAYOR ADVERSE
CARDIOVASCULAR EVENTS IN PATIENTS WITH
ACUTE MYOCARDIAL INFARCTION TREATED WITH
PRIMARY PERCUTANEOUS
C0385 MORTALITY AFTER PREGNANCY-RELATED VENOUS
THROMBOSIS
Hilde Skuterud Wik, Anne Flem Jacobsen, Leiv Sandvik,
Per Morten Sandset
C0167 PREGNANCY AND LABOR IN PATIENTS WITH HISTORY OF ISCHEMIC STROKE.
Tina Kocica, Nebojsa Antonijevic, Nebojsa Savic, Lazar
Davidovic
Alexander Makatsariya, Viktoriya Bitsadze, Dzhamilya
Khizroeva, Svetlana Akinshina
C0278COMPARATIVE EFFECTIVENESS OF DIFFERENT
DOSES ANTIPLATELET THERAPY AND FORMS ACETYLSALICYLIC ACID IN PATIENTS WITH STABLE ANGINA
CO14: Thrombophilia (Auditorium Hermès)
Chairs: Turgut Ulutin and Ulrich Abildgaard
Oksana Demyanenko, Valeriy Vishnevskiy
C0229 REGULATORY REGIONS OF SERPINC1 GENE: IDENTIFICATION OF THE FIRST MUTATION ASSOCIATED
WITH ANTITHROMBIN DEFICIENCY.
C0279 HYPERCHOLESTEROLEMIA - A RESISTANCE FACTOR IN ANTIPLATELET THERAPY
María Eugenia de la Morena-Barrio, Ana Isabel Antón,
Irene Martínez-Martínez, Jose Padilla, Antonia Miñano,
Jose Navarro-Fernández, Sonia Águila, María Fernanda
López, Jordi Fontcuberta, Vicente Vicente, Javier Corral
C0075 TYPE II ANTITHROMBIN DEFICIENCY CAUSED BY
A LARGE IN-FRAME INSERTION. STRUCTURAL,
FUNCTIONAL AND PATHOLOGICAL RELEVANCE.
Irene Martínez-Martínez, Daniel J.D. Johnson, Masayuki Yamasaki, José Navarro-Fernández, Adriana Ordóñez,
Vicente Vicente, James A. Huntington, Javier Corral
Valeriy Vishnevskiy, Oksana Demyanenko
16:00
End of the Congress
Poster Session
17:50-18:30
Posters Session (PS1) (Foyer)
P0018 New mutation SS => 125 in DVT
Jean-François Schved
P0024 Nicotinic acid/laropiprant addition to chronic lipid
apheresis in very high-risk patients with acute coronary
syndromes.
Gabriele Cioni, Rossella Marcucci, Lucia Mannini, Sandra Fedi,
Stefano Bucci, Alfredo Sabato, Rosanna Abbate, Giovanna D’Alessandri
P0028 Efficacy and safety Koagil-VII (JSC “Pharmstandard”)
administration after cardiac surgery in patients with
high bleeding risk
Galina V. Lobacheva, Mikhail M. Rybka, Natalia N. Samsonova,
Elena F. Kozar
P0050 Eplerenone, a new selective mineralocorticoid receptor
antagonist, inhibits platelet adhesion and attenuates
endothelial damage in arterial thrombosis model in
diabetic rats.
Ewa Chabielska, Urszula Bycul, Agnieszka Zakrzeska, Piotr Szoka,
Wioleta Kisiel, Irena Kasacka
P0064 Adrenal gland-dependent process of arterial thrombus
formation in diabetic rats
Piotr Szoka, Agnieszka Zakrzeska, Urszula Bycul, Wioleta Kisiel, Irena
Kasacka, Ewa Chabielska
P0065 WHITE BLOOD CELL COUNT MEASURED PRIOR TO CANCER
DEVELOPMENT IS ASSOCIATED WITH FUTURE RISK OF VENOUS
THROMBOEMBOLISM IN CANCER PATIENTS – THE TROMSØ STUDY
Hilde Jensvoll, Kristine Blix, Sigrid Brækkan, John-Bjarne Hansen
P0084 The effect of CME educational programs on VTE morality &
morbidity in King Fahad Hospital – Jeddah –KSA
Essam AboElNazar, Fahd Alhameed
P0088 DIFFERENTIAL ASSOCIATIONS BETWEEN EDUCATIONAL LEVEL AND
FUTURE RISK OF VENOUS THROMBOEMBOSLISM AND MYOCARDIAL
INFARCTION. THE TROMSØ STUDY.
Kristin F. Enga, Knut Gjelland, Sigrid K. Brækkan, John-Bjarne
Hansen
P0092 Predictive factors for venous recanalisation after first
idiopathic venous thrombosis
Tjasa Vizintin-Cuderman, Monika Stalc, Alenka Mavri
P0093 HEMATOCRIT MEASURED PRIOR TO CANCER DEVELOPMENT IS NOT
ASSOCIATED WITH FUTURE RISK OF VENOUS THROMBOEMBOLISM
IN CANCER PATIENTS – THE TROMSØ STUDY
Hilde Jensvoll, Kristine Blix, Sigrid Brækkan, John-Bjarne Hansen
P0103 MEDITERRANEAN PARADOX: DOES IT EXIST IN VENOUS
THROMBOEMBOLIC DISEASE
Juan Francisco Sanchez Muñoz-Torrero, Alicia Lorenzo
Hernández, Javier Trujillo
P0104 EVOLUTION OF VENOUS THROMBOEMBOLIC DISEASE IN PATIENTS
WITH DIABETES: RISK OR PROTECTOR FACTOR?
Alicia Lorenzo Hernández, Maria Del Carmen Fernández
Capitán, Sarah Caro Bragado, Maria De Los Angeles Rodriguez Dávila,
Mikel Rico Briñas, Maria Fernández Velilla, Maria Cuesta, Maria Isabel
Torres Sánchez
P0105 DIABETIC PATIENTS AND VENOUS THROMBOEMBOLIC DISEASE. IS
THERE ANY DIFFERENCE?
María Del Carmen Fernández Capitán, Alicia Lorenzo Hernández,
Sarah Caro Bragado, María Angeles Rodriguez Dávila, Mikel Rico Briñas,
Marina Triguero Genao, María Fernández Velilla, María Osabel Torres,
María Isabel Torres
P0106 DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM: SAME
DISEASE IN DIABETIC PATIENTS?
Alicia Lorenzo Hernández, María Del Carmen Fernández
Capitán, Juan Francisco Sánchez Muñoz-Torrero, Mikel Rico Briñas,
Marina Triguero Genao, Georgina Salgueiro, María Fernández Velilla,
María Isabel Torres Sánchez, Maria Angeles Rodriguez Davila
P0110 SERUM LEVELS OF VITAMIN D IS NOT ASSOCIATED WITH FUTURE
RISK OF VENOUS THROMBOEMBOLISM – THE TROMSØ STUDY
Ellen Brodin, Gunhild Lerstad, Guri Grimnes, Sigrid K Brækkan,
Johan Svartberg, Rolf Jorde, John-Bjarne Hansen
P0135 In vitro and in silico study of the effect of crocin and
safranal on human plasma coagulation
Maria Ditsa, George Geromihalos, Eleftheria Tragoulia, Dimitra
Markala, Chrisa Meleti, Zaxarias Sinakos
P0144 The comparison of two different antithrombotic regimens
in patients with atrial fibrillation for the prevention of
ishaemic stroke
Sladjana Novaković-Anučin, Sanja Gnip, Višnja Čanak, Pavica
Radović, Milena Šćekic, Jelena Kovačev, Gorana Mitić
P0145 Haemostatic System Changes in Orthotopic Liver
Transplantation - single center experience
Sladjana Novaković-Anučin, Sanja Gnip, Višnja Čanak, Djurdjina
Jurišić, Pavica Radović, Svetlana Erdeljan, Zoran Milošević,
Gorana Mitić
P0150 The features of antiplatelet therapy in inflammation
Liudmila Buryachkovskaya, Alexander Sumarokov, Irina Uchitel
P0151 The role of p-selectin in deep venous thrombosis: a metaanalysis
Constantine Antonopoulos, Triantafillos Giannakopoulos,
Aristeidis Kallinis, Ioannis Vasilopoulos, Ilias Dalainas, John Kakisis,
Christos Liapis
P0153 Evaluation of atrial fibrillation population in Apulia
region for the cost/effectiveness analysis for the use
of old and new oral anticoagulants: cooperation of
hematologist, cardiologist and internist
Nicola Ciavarella, Paolo Colonna, Ennio Michelotto, Vito Lepore,
Fabio Robusto, Elvira Grandone, Luigi Ria, Giacomo Lucarelli, Salvatore
Bradamante, Michele Virgilio, Gianfranco Antonelli, Pasquale Caldarola,
Carlo D’Agostino, Stefano Favale, Giovanni Tognoni
P0159 β1 blockers, warfarin and rhythm conversion in atrial
fibrillation
Ruzan Durgaryan
P0163 Role of A3 haplotype of EPCR in the development of deep
vein thrombosis in Asian Indian.
Amit Sharma, Arijit Biswas, Ravi ranjan, Mohd. Suhail Akhter, Ravi
kumar, Kamal Kishor, Renu Saxena
P0168 The APCR ratio is differently influenced by warfarin
therapy when different assays are used.
Petr Kessler, Hynek Poul, Arnost Komarek, Maria Kusnierova,
Michaela Harudova
P0169 Cave thrombosis in Behçet’s disease: A report of 29 cases.
Ben Ghorbel Imed, Belfeki Nabil, Said Fatma, Ben Salem
Thouraya, Lamloum Mounir, Braham Amel, Khanfir Monia, Hamzaoui
Amira, Houman Habib
P0172 Unusual complication in Wegener’s granulomatosis: deep
venous thrombosis. About four cases.
Ben Ghorbel Imed, Belfeki Nabil, Braham Amel, Lamloum Mounir,
Ben Salem Thouraya, Khanfir Monia, Hamzaoui Amira, Houman Habib
P0178 CYP2C9 and VKORC1 gene polymorphisms in the healthy
Russian and Buryat respondents in Transbaikalia
Olga Stepanova, Marine Avetisyan, Yuri Vitkovsky
P0179 DEEP VEIN THROMBOSIS OF UPPER EXTREMITIES(UEDVT): A
TERTIARY CENTER’S EXPERIENCE
Anastasia Banti, Emmanouil Papadakis, Vassilios Papadopoulos,
Konstantinos Loukidis, Dionysia Theocharidou, Smaragda Efraimidou,
Anna Karagianni, Vaia Papageorgiou, Vassiliki Pissanidou, Parthena
Kapali, Anna Kioumi
P0181 The association of functional polymorphisms of IL-6 gene
promoter With ischemic stroke.
Mohd. Suhail Akhter, Arijit Biswas, Ravi Ranjan, Amit Sharma,
kamal kishor, Renu Saxena
P0183 Atypical Hemolytic- Uremic syndrome by deficit in MCP
diagnosed at a teenager
Hedouas Meriem, Khedri Nassima
P0185 Can overall haemostasis potential (OHP) discriminate
between patients who will suffer early restenosis after
femoropopliteal percutaneous transluminal angioplasty
(PTA) from those who will not?
Maja Vučnik, Vinko Boc, Aleš Blinc, Matjaž Vrtovec, Rok Perme,
Barbara Krevel, Matija Kozak, Petra Malovrh, Barbara Eržen, Mojca
Božič-Mijovski, Mojca Stegnar
P0186 HOMOCYSTEINE AND Lp(a) IN PATIENTS WITH ISCHAEMIC
CEREBROVASCULAR ACCIDENTS
Aikaterini Hasiou, Michail Hasios, Paraskevi Karapavlidou,
Anastasia Dimitrouli, Ioanna Passalidou
P0206 EFFECTIVENESS AND SAFETY OF ARGATROBAN IN THE ACUTE
TREATMENT OF DEEP VEIN THROMBOSIS IN PATIENT WITH ALLERGY
TO HEPARIN UNDERGOING RENAL REPLACEMENT THERAPY: A CASE
REPORT
Matteo Giorgi-Pierfranceschi, Roberto Scarpioni, Sergio
Ballocchi, Vittorio Albertazzi, Stefania D’Amore, Sara De Amicis, Marco
Ricardi, Piergiorgio Poisetti
P0225 DIGITAL TV AND MOBILE DEVICES TO INCREASE THE COMPLIANCE/
PERSISTENCE TO MEDICINES IN CHRONIC SUBJECTS ON ORAL
ANTICOAGULANT DRUGS: THE PILOT STUDY
Giovanni Dirienzo, Nicola Ciavarella, Lino Renna, Nicola Pansini,
Michele Virgilio
P0232 Curcumin attenuates inflammatory and thrombotic
events induced by repeated pulmonary exposure to diesel
exhaust particles in mice
Abderrahim Nemmar, Deepa Subramaniyan, Badreldin Ali
P0239 Which are the most evidence-based and cost-effective
strategies for treating patients with heart failure?
Jennifer Creed
P0287 Assessment of endothelial function by peripheral
arterial tonometry in patients with previous acute
coronary syndrome identifies systemic atherosclerosis
independently of traditional risk factors.
Gabriele Cioni, Rossella Marcucci, Francesca Cesari, Serafina
Valente, Cristina Giglioli, Rosanna Abbate, Maria Boddi
P0292 LIPID LEVELS AND RISK OF VENOUS THROMBOSIS
Aránzazu García Raso, Raquel Mata, Rosa Vidal, Sol Sánchez, Pilar
Llamas
P0294 DEEP VENOUS THROMBOSIS IN PATIENTS WITH No O- GROUP
Aránzazu García Raso, Raquel Mata, Elham Askari, Claudia Gorcea,
Pilar Llamas
P0305 DEEP VEIN THROMBOSIS AND MALFORMATIONS OF INFERIOR VENA
CAVA
Ruth Calderón Hernáiz, Justo Ruiz Ruiz, Olga Mateo Rodriguez,
Diego Orlando Rejas Velasquez, Elena Madroñal Cerezo, Rosa María
Martín Díaz, Alicia Castro Gordon, María Fernández López, Jesús Canora
Lebrato, Antonio Zapatero Gaviria
P0307 Baseline characteristics and management of patients
with splanchnic vein thrombosis: results of an
International Registry
Walter Ageno, Nicoletta Riva, Sam Schulman, Soo-Mee Bang, Maria
Teresa Sartori, Elvira Grandone, Jan Beyer, Giovanni Barillari, Dario Di
Minno, Rita Duce, Alessandra Malato, Rita Santoro, Daniela Poli, Peter
Verhamme, Ida Martinelli, Pieter Kamphuisen, Adriano Alatri, Doyeun
Oh, Elbio D’Amico
P0309 VENA CAVA THROMBOSIS IN BEHCET DISEASE
Bellakhal Syrine, Hamzaoui Amira, Saïd Fatma, Ben Salem Thouraya,
Smiti-Khanfir Monia, Braham Amel, Ben Ghorbel Imed, Lamloum
Mounir, Houman Mohamed-Habib
P0318 NEUROLEPTIC DRUGS AND VENOUS THROMBOEMBOLIC DISEASE
María Jesús Jaras Hernández, Jose Francisco Pascual Pareja, Alicia
Lorenzo Hernández, Mar Matin Pozo, José.M Luque. Pinilla,
Javier Gutierrez Guisado, Olga Madridano Cobo, M.Angeles Rodriguez
Dávila, Carmen Fernández Capitán
P0320 Oral anticoagulation in atrial fibrillation, the patients
and physicians experiences of the consultation; a
qualitative study.
Christian Borg Xuereb, Rachel L. Shaw, Gregory Y.H. Lip, Deirdre
A. Lane
P0325 A 40 years survey of pulmonary embolism documented
at autopsy in a tertiary care hospital from Cordoba,
Argentina
Aldo Hugo Tabares, Romina Montivero, Rosio Baena Terán, Carina
Seculini, Andres Arancibia, Luciana Guanchiale, Ana Diller, Juan García
P0335 Vitamin K antagonists treatment and endogenous
thrombin potential in patients with venous
thromboembolism.
Veronika Shmeleva, Yriy Namestnikov, Olesya Matvienko, Vitaly
Soldatenkov
P0336 Venous thromboembolism (VTE) at rare sites in neonates
and children
Pergantou Helen, Avgeri Maria, Komitopoulou Anna, Xafaki
Panagiota, Kapsimali Zoey, Karelioti Helen, Platokouki Helen
P0359 Characteristics of Deep venous thrombosis in Tunisian
Behçet’s disease patients
Bellakhal Syrine, Saïd Fatma, Ben Salem Thouraya, Hamzaoui Amira,
Braham-Sfaxi Amel, Smiti-Khanfir Monia, Ben Ghorbel Imed, Lamloum
P0368 A feverish lumbago at a patient with a Behçet’s disease in
remission : think of the thrombosis of the renal vein
Mounir Lamloum, Mounir Lamloum, Imène Rachdi, Imed Ben
Ghorbel, Thouraya Ben Salem, Amira Hamzaoui, Monia Khanfir, Amel
Braham, Mohamed Habib Houman
P0370 Plasma levels of soluble CD36, platelet activation,
inflammation and oxidative stress are increased in type 2
diabetic patients
Simona Sestili, Francesca Santilli, Bente Halvorsen, Aase Handberg,
Rossella Liani, Natale Vazzana, Gloria Formoso, Pål Aukrust, Giovanni
Davì
P0371 Venous thrombosis in amebic colitis
Mounir Lamloum, Imène Rachdi, Imed Ben Ghorbel, Amira
Hamzaoui, Thouraya Ben Salem, Monia Khanfir, Amel Braham, Mohamed
Habib Houman
P0373 Venous thrombosis revealing a Crohn’s disease
Hamzaoui, Thouraya Ben Salem, Monia khanfir, Amel Braham, Mohamed
Habib Houman
P0376 Venous thrombosis revealing a multiple myeloma
Hamzaoui, Thouraya Ben Salem, Monia khanfir, Amel Braham, Mohamed
Habib Houman
P0389 Inflammation, oxidative stress and platelet activation in
aspirin-treated critical limb ischaemia: beneficial effects
of iloprost.
Natale Vazzana, Gianfranco Lessiani, Chiara Cuccurullo, Dario Di
Michele, Giuseppe Laurora, Giuseppe Sgrò, Paolo Di Ruscio, Emilio
Simeone, Pierangelo Di Iorio, Stefano Lattanzio, Rossella Liani, Giovanni
Davì
P0392 Cancer-associated thrombosis; a study of 806 cases of
deep venous thrombosis
Smiti Khanfir Monia, Bellakhal Syrine, Hamzaoui Amira, Ben Salem
Thouraya, Braham Amel, Ben Ghorbel Imed, Lamloum Mounir,
Houman Mohamed Habib
P0393 Risk factors and prevalence of venous thromboembolism
in internal medicine: A retrospective study of 806 patients
Bellakhal Syrine, Smiti Khanfir Monia, Hamzaoui Amira, Said Fatma, Ben
Salem Thouraya, Braham Amel, Lamloum Mounir, Ben Ghorbel Imed,
P0395 Hyperhomocysteinemia, thrombosis and pernicious
anemia. Four new cases.
Tazi Mezalek Zoubida, Ammouri Wafaa, Harmouche Hicham,
Maamar Mouna, Adnaoui Mohamed, Aouni Mohamed
P0396 Venous thrombosis revealing celiac disease. Three cases.
Tazi Mezalek Zoubida, Benecer Alaoui Habiba, Harmouche
Hicham, Bachir Houda, Maamar Mouna, Adnaoui Mohamed, Aouni
Mohamed
P0397 Thromboembolitic events in patients with systemic
Vasculitis
Bellakhal Syrine, Hamzaoui Amira, Hajji Raouf, Smiti-Khanfir Monia,
Ben Salem Thouraya, Braham-Sfaxi Amel, Ben Ghorbel Imed, Lamloum
P0408 Case report: Oral contraceptives, thrombophilias and deep
vein thrombosis in young women after tonsillectomy
Tiha Vucemilo, Marija Skoko, Deana Sturm
P0409 Prevalence of atrial fibrillation in patients presenting
with stroke
Uchenna Ozo, Khalil Peroo, Gemma Fitzpatrick, Khalil Kawafi
P0418 Use of thrombopoietin mimetics in Acute ITP
Ashwini Arumugaswamy, Simon He, Hang Quach, Andrew Grigg
P0426 ENDOTHELIAL PROTEIN C RECEPTOR GENE POLYMORPHISMS AND
RISK OF VENOUS THROMBOSIS IN YOUNG PATIENTS
Georgia Anastasiou, Argyri Gialeraki, Eufrossyni Merkouri,
Loukianos Rallidis, Anthi Travlou
P0428 Visualization of the platelet function
Makris Pantelis, Makris Michael
12:45-13:45
P0079 TF/TFPI in chronic myeloproliferative disorders.
Danuta Rosc, Katarzyna Stankowska, Joanna Boinska, Grazyna
Gadomska, Ewa Zekanowska, Wojciech Swistek
P0095 Circulating endothelial cells and microparticles as
prognostic markers in advanced Non-Small-Cell Lung
Cancer
Tania Fleitas, Vicenta Martínez-Sales, Virtudes Vila, Edelmiro
Reganon, David Mesado, María Martín, José Gómez-Codina, Joaquín
Montalar, Gaspar Reynés
P0097 Microparticles and markers of coagulation, inflammation
and angiogenesis in patients with glioblastoma before
and after treatment with temozolomide and radiation
therapy: Prognostic value
Virtudes Vila, Gaspar Reynés, Tania Fleitas, María Martín, Edelmiro
Reganon, Vicenta Martínez-Sales
P0098 High levels of microparticles and markers of coagulation
and inflammation distinguish decompensated heart
failure vs to stable phase.
Virtudes Vila, Ignacio Sánchez-Lázaro, Luis Almenar, Vicenta
Martínez-Sales
P0099 KINETICS AND MECHANISM OF INHIBITION BY ANGIOSTATIN OF
PLASMINOGEN ACTIVATION UNDER THE ACTION OF UROKINASE
AND TISSUE PLASMINOGEN ACTIVATOR
Lilia Mukhametova, Roza Aisina, Karina Gershkovich, Dmitrii
Gulin
P0100 THE CONTRIBUTION OF FIBRINOLYSIS IMPAIRMENT TO THE
DEVELOPMENT ON THROMBOSIS IN ANTIPHOSPHOLIPID SYNDROME
(APS)
Roza Aisina, Lilia Mukhametova, Tatiana Reshetnyak, Ekaterina
Ostryakova, N Seredavkina, N Patrusheva, Lev Patrushev, Dmitrii Gulin,
Karina Gershkovich
P0118 Diagnostic difficulties for the detection of lupus
anticoagulant: experience of the hematology laboratory
at Charles Nicolle Hospital of Tunis.
Ben Said Mehdi, Kallel Hajer, Chaker Farah, Ellouze Rym, Guermazi
Sami
P0119 Therapeutic Approach to Venous Paraneoplastic
Thromboembolism. Experience From a Single Center
Irene García-Cadenas, Amparo Santamaria, Jordi Fontcuberta
P0120 Thromboembolic Events in Oncological Patients: A Single
Center Experience.
Irene García-Cadenas, Amparo Santamaria, Jordi Fontcuberta
P0124 Assessment of risk factors for venous thromboembolism
in women with breast carcinoma
Zeljko Kovac, Mirjana Kovac, Valentina Djordjevic, Zorica
Tomasevic, Iva Pruner, Dragica Radojkovic
P0132 INVESTIGATING ANTIPLATELET ACTIVITY OF RED AND WHITE WINE
Eleftheria Tragoulia, Maria Ditsa, Chrisa Meleti, Katerina Mparmpouti,
Dimitra Markala
P0134 Internet based questionnaire for the analysis of
preference of patients for anticoagulants
Zolfaghari Shabnam, Marx Svetlana, Abou Ayash Nadja, Kremer
Christophe, Hoeing Vera, Schirk katrin, Weiss Christel, Frölich Lutz,
Harenberg Job
P0137 XAMOS: a large non-interventional study in patients
undergoing major hip or knee replacement surgery and
receiving oral rivaroxaban or conventional regimens
for thromboprophylaxis
Sylvia Haas, Alexander GG Turpie, Waheed Jamal, André Schmidt,
Michael Rud Lassen, Lorenzo Mantovani, Reinhold Kreutz
P0138 UTILIZATION OF WAVEFORM ANALYSIS OF ACTIVATED PARTIAL
THROMBOPLASTIN TIME (APTT)- CLINICAL AND PROGNOSTIC
VALUE.
Eleftheria Tragoulia, Maria Ditsa, Poly Kazila, Chrisa Meleti,
Anastasia Mpanti, Efi Yannaki, Dimitra Markala
P0141 Radiotherapy and platelets activation in patients with
prostate cancer
Ewa Zekanowska, Danuta Rystok-Grabska, Tomasz Wisniewski,
Ewa Ziółkowska, Artur Słomka, Paulina Giemza-Kucharska, Danuta Rosc
P0148 Platelets coxsackie adenovirus receptor (CAR) in normal
and inflammatory cardiac pathology.
Elena Gupalo, Liudmila Buryachkovskaya, Pyotr Chumachenko,
Natalia Mironova
P0161 Lymphocyte-platelet adhesion in patients with chronic
brain ischemia, carried IL-10 (G-1082A), IL-10 (C-819T)
polymorphisms
Anna Knyazeva, Nataliya Strambovskaya, Yuri Vitkovsky
P0162 Analysis of the use of fibrinogen to treat acquired
coagulopathies in a Portuguese Hospital
Jorge Martinez, Patricia Amantegui, João Ribeiro, Inês
Eusébio, Rita Moras, Rita Oliveira, Olímpia Fonseca, Ana
Ramalhinho
P0164 Clinical case report: patient with severe postpartum
hemorraghe treated with high doses of fibrinogen
concentrate
Jorge Martinez, Patricia Amantegui, João Ribeiro, Inês Eusébio,
Rita Moras, Rita Oliveira, Olímpia Fonseca, Ana Ramalhinho
P0165 Cerebral Venous Thrombosis and Paroxysmal Nocturnal
Hemoglobinuria: A Series of 12 Cases
Meppiel Elodie, Crassard Isabelle, Peffault De Latour
Régis, Chabriat Hugues, Socie Gérard, Bousser MarieGermaine
P0173 High levels of von Willebrand factor antigen and
procoagulant factor VIII found in multiple myeloma
patients are associated with activity status
Juraj Sokol, Emília Flochová, Juraj Chudej, Radoslava
Šimonová, Daniela Chudá, Peter Chudý, Ján Staško,
Peter Kubisz
P0177 The participation of gamma/delta and alfa/beta Tlymphocytes in coagregates forming with platelets
Alexey Solpov, Petr Tereshkov, Yuri Vitkovsky
P0184 THE ANALYSIS OF CELL IMAGE OF PLATELETS IN VENOUS BLOOD OF
PATIENTS WITH IDEOPATHIC TROMBOCYTOPENIC PURPURA
Irina S. Kastrikina, Gennady I. Kozinets, Valery M.
Pogorelov, Lidiya G. Kovaleva, Elena I. Pustovaya, Marem
I. Chanieva, Svetlana N. Bytchkova
P0191 ACUTE MYOCARDIAL INFARCTION AND NATURAL COAGULATION
INHIBITORS
Michail
Hasios,
Aikaterini
Hasiou,
Paraskevi
Karapavlidou, Ioanna Passalidou
P0194 A NEW ORAL ANTICOAGULANT (DABIGATRAN ETEXILATE):
AVAILABILITY OF LABORATORY MONITORING
Vladimir Sukhanov, Olga Petrova
P0197 Evaluation of bleeding symptoms in case of inherited FVII
deficiency: about 9 cases
Ben Lakhal Fatma, El Borgi Wijdene, Ben Salah Naouel, Zahra
Kaouther, Meddeb Balkis, Hafsia Raouf, Gouider Emna
P0200 Clinical and Biological features of Von Willebrand
disease type 3: report of a Tunisian series.
Kaouther, Zorguan Moez, Meddeb Balkis, Hafsia Raouf, Gouider Emna
P0204 Factor XIII deficiency: a family report
Kaouther, Zorguan Moez, Mahmoudi Hajer, Meddeb Balkis, Hafsia Raouf,
Gouider Emna
P0205 SEVERE THROMBOTIC EVENTS IN YOUNG PATIENTS WITH
ANTIPHOSPHOLIPID SYNDROME
Florencia Sundberg, Graciela Pedreira
P0215 The occurrence of thrombo-haemoragic events in
patients with polycythaemia vera and essential
thrombocythaemia in relationship to presentation of
JAK2V617F mutation.
Zuzana Jedinakova, Jan Stasko, Daniela Chuda, Juraj Marcinek,
Tatiana Burjanivova, Juraj Sokol, Peter Kubisz
P0219 Inherited factor XI deficiency: a report of 11 cases and
review of literature
Elborgi Wijdene, Ben Lakhal Fatma, Ben Salah Naouel, Zahra
P0220 Incidence of hemophilia in the North of Tunisia
Elborgi Wijdene, Ben Lakhal Fatma, Ben Salah Naouel, Zahra
P0236 PRE-ANALYTICAL CONDITIONS OF CENTRIFUGATION AND FREEZING
BUT NOT TEMPERATURE AFFECT MP LEVELS
Virtudes Vila, Silvia Navarro, Verónica Sánchez-López, Remedios
Otero, Vicenta Martínez-Sales
P0248 MPTP-dependent and -independent mechanisms of platelet
apoptosis: Effects of cyclosporin A
Valery Leytin, Armen Gyulkhandanyan, Asuman Mutlu, Sergiy
Mykhaylov, David Allen, John Freedman
P0249 Elastase-mediated
fibrinolysis
in
disseminated
intravascular coagulation (DIC) associated with sepsis
Takeshi Wada, Satoshi Gando, Yuichiro Yanagida, Shinji Uegaki,
Nobuhiko Kubota, Mineji Hayakawa, Atsushi Sawamura, Subrina Jesmin
P0257 Rituximab in Refractory Antiphospholipid Syndrome
Abdul Kareem Almomen, Sri-Halimah Cana, Rana Hasanato,
Abdullah Abujamea
P0259 THROMBIN GENERATION AND CONVENTIONAL COAGULATION
MARKERS IN PATIENTS WITH HYPERCOAGULABLE STATE DUE TO
LOW PT AND/OR APTT
Evmorfia Papakonstantinou, Efstathios Yfantis, Anneta
Theofani, Amalia Skourbouti, Paraskevi Georgutsu, Panagiotis Safioleas,
Christina Sereti, Christina Manti
P0261 THROMBIN GENERATION PARAMETERS IN ACUTE MYOCARDIAL
INFRACTION, MULTIPLE MYELOMA AND IN MYELOPROLIFERATIVE
DISORDERS
Evmorfia Papakonstantinou, Efstathios Yfantis, Anneta
Theofani, Anthi Lakoumenta, Aikaterini Lavda, Christos Pegos,
Konstantinos Safioleas, Christina Manti
P0264 PROTEIN Z MUTATIONS IN PATIENTS WITH FETAL LOSSES:
STRUCTURAL ANALYSIS
Giovanni, Luca Tiscia, Rocco Caliandro, Giovanni Nico, Valerio De
Stefano, Elena Rossi, Tommaso Za, Giovanni Favuzzi, Filomena
Cappucci, Lucia Fischetti, Donatella Colaizzo, Francesco Giuliani,
Elvira Grandone
P0267 Genotype-Phenotype relationship in Italian subjects with
congenital FXI deficiency
Giovanni Favuzzi, Giovanni, Luca Tiscia, Elena Chinni, Donatella
Colaizzo, Valeria Bafunno, Gennaro Vecchione, Maurizio Margaglione,
Elvira Grandone
P0271 Platelets GPIBA and ITG A2 polymorphisms in the healthy
Russian and Buryat respondents in Transbaikalia
Marine Avetisyan, Olga Stepanova, Yuri Vitkovsky
P0273 CENTRAL VENOUS CATHETER-RELATED THROMBOSIS IN PATIENTS
WITH ACUTE LEUKEMIA
Irena Djunic, Marijana Virijevic, Aleksandra Novkovic, Nada
Suvajdzic-Vukovic, Ivo Elezovic, Predrag Miljic, Ana Vidovic, Natasa
Coloovic, Dragica Tomin
P0274 Smoking and other risk factoris in patients with acute
myocardial infarction in southern Croatia
Duska Glavas, Katarina Novak
P0277 EXPERIENCE IN THE USE OF INTRAVENOUS IMMUNOGLOBULIN
IN PREGNANT WOMEN WITH RECURRENT MISCARRIAGES AND
ANTIPHOSPHOLIPID SYNDROME
Dina Eremeeva, Marina Zaynulina
P0280 Correlation beetween AnnexinV-FITC and Annexin V-V450
Positive Microparticles in two high sensitivity cytometers
Verónica Sánchez-López, Virtudes Vila, Vicenta MartinezSalas, Emilia Martín-Rodriguez, Ana Montes-Worboys, Elena Arellano,
Teresa Elias, Remedios Otero
P0299 Thrombosis in newborns and neonates. Unsolved
problems.
Eugene Roitman, Alexandr Rumyantsev, Andrey Momot,
Nicolay Volodin, Maria Shnader, Maria Shnader
P0300 Measurement of rivaroxaban in urine by a point of care
method
Job Harenberg, Astrid Schulze, Christina Giese, Sandra Krämer,
Shanshan Du, Misael Schleger, Roland Krämer
P0301 Bleeding in four patients with excessive response to
dabigatran: implications for emergency surgery and
resuscitation.
Agnès Lillo-Le Louët, Martine Wolf, Michel-Meyer Samama
P0306 ACCURACY
OF
EMERGENCY
PHYSICIAN–PERFORMED
ULTRASONOGRAPHY IN THE DIAGNOSIS OF DEEP VEIN THROMBOSIS:
a systematic review and a meta-analysis of the literature
Fulvio Pomero, Francesco Dentali, Valentina Borretta, Matteo
Bonzini, Remo Melchio, James D Douketis, Luigi M Fenoglio
P0333 Management of Recurrent Abortion in Afibrinogenemia
Woman
Manijeh Lak
P0337 Hyperhomocysteinemia as marker of higher thrombotic
risk in patients with multiple myeloma.
Veronika Shmeleva, Ecaterina Chait, Kudrat Abdulkadirov,
Stanislav Bessmeltsev
P0342 Exposure to hypoxic environment results in altered
platelet proteome and reactivity
Tarun Tyagi, Shadab Ahmad, Tathagat Chatterjee, Neha Gupta,
Yasmin Ahmad, Shantanu Sengupta, M.Zahid Ashraf
P0352 Evolution of thrombin generation (endogenous and
exogenous pathway) in parallel with the anti-FVIII
inhibitor level in a patient with acquired haemophilia,
treated with MABTHERA. In vitro response to the addition
of NOVOSEVEN.
Mazoyer Elisabeth, Guinet Céline, Duflot Sandrine, Dhote Robin,
Samama Michel Meyer
P0358 UNDERSTANDING RECURRENT THROMBOSIS OF ANTIPHOSPHOLIPID
SYNDROME.
Harberth Fernandez, Nuria Bermejo Vega, Carolina Martin
Aguilera, Fernando Carnicero, Fatima Ibañez Espacio, Maria Jose Arcos
Carmona, Maria Elena Bañas, Carmen Cabrera Silva, Julio Prieto, Maria
Jose Garcia Blanco, Marisa Martin Mateos, Juan M. Bergua Burgues
P0377 Does FVL have an effect on longevity?
Dilara Fatma Akın, Yonca Eğin, Nejat Akar
P0384 Severe thrombocytopenia and metachronous dilated
superficial veins and thrombosis: infection, autoimmune
disorder or LGL cytopenia?
Efthymia Rigatou, George Paterakis, Helen Platokouki, Kleoniki
Roka, Georgia Avgerinou, Vassilios Papadakis, Sophia Polychronopoulou
P0390 Fibrinolytic activity and d-dimer in Behçet’s disease
Belfeki Nabil, Smiti Khanfir Monia, Hamzaoui Amira, Ben Salem
Thouraya, Baccouche Hela, Mahjoub Sonia, Ben Romdhane Neila,
P0391 Disseminated intravascular coagulation in familial
lymphohistiocytosis: a cytokin thunderstorm
Daghor Abbaci Karima, Hakem Djennette, Berrah Abdelkrim
P0398 Does buffy coat prepared for autologous stem cell
transplantation in cancer patients has procoagulant
properties? An in vitro study.
Sidibe Fatoumata, Vassiliki Galea, Robert Françoise, Romain
Marie Paule, Bernaudin Jean François, Lotz Jean Pierre, Selle Fréderique,
Larghero Jerome, Hatmi Mohamed, Van Dreden Patrick, Gerotziafas
Grigoris, Elalamy Ismail
P0400 Relation between thrombotic symptoms and fibrin
generation kinetics in patients with dysfibrinogenemia
Virtudes Vila, Elena Mesa, Saturnino Haya, Ana Cid, Jose Antonio
Aznar
P0405 Carotid artery thrombosis secondary to penetrating
neck trauma
Hamid Jiber
P0406 The relationship platelet glycoprotein IIb rs 5911
polymorphism and prognostic parameters in female
Turkish patients with breast cancer
Ilyas Samet Ergün, Hilal Altınöz, Z Oya Uyguner, Nusret Erdoğan, Turay
Yardımcı, Şermin Tetik
P0407 CHICKENPOX IS NOT ALWAYS BENIGN: POSTVARICELLA PURPURA
FULMINANS DUE TO ACQUIRED DEFICIENCY OF PROTEIN S
M Angeles Dasi, Bienvenida Argiles, Sara Izquierdo, Magdalena
Peinador
P0414 Why do children bleed and clot less than adults?
Understanding the maturation of the haemostatic
system.
Vera Ignjatovic, Paul Monagle
P0423 The Sonographer and Ultrasound Gel
Bosler Frederic
P0432 Potential to prevent thrombosis by releasing intrinsic
tissue-type plasminogen activator by Enzamin
Osamu Matsuo, Yukinori Tamura
13:00-14:00
P0025 Venous thromboembolism and factor V Leiden: enigma or
paradox.
Francisco Gabriel, Olga Portolés, Manuel Labiós, C Rodriguez, E
Cisneros, JR Vela, MJ Nuñez
P0026 Contemporary prophylaxis of postoperative venous
thromboembolism and monitoring of efficacy:
accumulated experience
Arshak Vardanyan, Robert Mumladze, Evgeniy Roitman, David
Dolidze, Mengkai Shieh
P0027 Mondor’s disease in young woman due to hereditary
thrombophilia
Asya Gusina, Nina Gusina
P0043 Association of MDR-1 Gene Polymorphism and Plasma
Platelet Activating Factor Levels in Patients with
Coronary Artery Disease
Turgut Ulutin, Gülsel Ayaz, Bilgehan Karadağ, Gönül Kanıgür,
Mehmet Güven, İlhan Onaran, Ahmet Dirican, Barış İlerigelen
P0045 Protein C Deficiency in a Family with a History of Childhood
Thrombosis
Anicee Danaee, Jayanthi Alamelu, David Bevan
P0048 Detection and characterization of novel double missense
mutations of SERPINC1 in type I inherited antithrombin
deficiency
Haoyu Deng, Wei Shen, Yi Gu, JiWei Zhang, Jun Xie, YiFeng He, Lan
Zhang
P0049 Is Serum Uric Acid a Predictor of New-Onset Diabetes in
Hypertensive Patients?
Gwo-Ping Jong, Tsochiang Ma
P0055 Patent Foramen Ovale: A Pathway for Myocardial
Infarction in Pregnant Patient – Case Report
Ene Mäeots, Merle Kadarik
P0073 CLINICAL MANIFESTATION IN HEREDITARY THROMBOPHILIAS AND
MANAGENEMT OF THROMBOSIS, PREGNANCY AND DELIVERY
Ivo Elezovic, Darko Antic, Predrag Miljic, Mirjana Mitrovic, Valentina
Djordjevic, Ljudmila Stojanovic, Olivera Markovic, Mirjana Kovac
P0086 High sensitivity of the global CIP assay for hereditary
thrombophilia
Orsolya Tóth, Jacqueline Conard, Hajna Losonczy, Barbara Réger,
Marianne S. Andresen, Marie-Hélene Horellou, Réka Mózes, Ulrich
Abildgaard
P0091 High levels of D-dimer and previous provoked venous
thromboembolism are risk factors for recurrent
idiopathic venous thrombosis
Monika Stalc, Tjasa Vizintin-Cuderman, Alenka Mavri, Anja Boc
P0111 Role of Inherited thrombophilia in Tunisian women with
recurrent pregnancy losses
Ellouze Rim, Kallel Hajer, Chaker Farah, Ben Said Mehdi, Guermazi
Sami
P0112 Activated protein C resistance in Tunisian patients with
thromboembolic complication or spontaneous recurrent
miscarriage
Chaker Farah, Ellouze Rim, Ben Said Mehdi, Kallel Hajer, Guermazi
Sami
P0123 Polymorphisms in the annexin A5 kozak sequence and
thrombosis disease in Tunisia
Mezni Imen, Sfar Imen, Ellouze Rym, Ben Said Mehdi, Bahloul
Abdessalem, Ben Romdhane Thouraya, Makhlouf Mouna, Ayed Jendoubi
Saloua, Ben Abdallah Taieb Khaled, Guermazi Sami, Gorgi Yousr
P0214 The influense of PAI-1 polyporfism on the platelets and
procoagulant parts of the microcoagulation of the
blood.
Ekaterina Shelest, Maria Matveeva, Ludmila Popova, Lev
Patrushev, Igor Bokarev
P0136 The Arg6Trp plasmin inhibitor polymorphism: does the
presence of the Trp6PI allele contribute to decreased risk
of myocardial infarction?
Ana Bronic, Goran Ferenčak, Robert Bernat, Jasna Leniček Krleza,
Jerka Dumić, Sanja Dabelić
P0216 Cytometric assessment of platelet P-selectin expression
in patients with sticky platelet syndrom.
Peter Kubisz, Peter Chudy, Daniela Chuda, Lenka Bartosova, Jan
Stasko
P0143 A retrospective study of thrombophilia testing requests
in a large teaching hospital
Michelle Kint, Sean Platton, Daniel Hart, Peter MacCallum, Laura
Green
P0152 INCIDENCE OF HAEMORRHAGIC AND THROMBOEMBOLIC
COMPLICATIONS IN PATIENTS WITH MECHANICAL HEART VALVE
PROSTHESES TAKING LONGTERM VITAMIN K ANTAGONISTS
Sanja Gnip, Sladjana Novakovic-Anucin, Visnja Canak, Pavica
Radovic, Jelena Kovacev, Milena Scekic, Gorana Mitic
P0154 Vicinal thiols are required for activation of the avb3
integrin in endothelial cells
Halszka Ponamarczuk, Izabela Papiewska-Pajak, Katarzyna Sobierajska,
Maria Swiatkowska
P0156 FII, TF, FV and MTHFR gene polymorphisms in the patients,
died from influenza A H1N1 (2009)
Antony Petrov, Olga Petrova, Nataliya Chartorizhskaya, Nataliya
Strambovskaya, Yuri Vitkovsky
P0157 Comparison of the Incidence of Treatment Complications
of Low Molecular Weight Heparin Use During Pregnancy
in Thrombophilic and Non-thrombophilic Women
Gorana Mitic, Mirjana Kovac, Aleksandra Novakov Mikic, Djurdjina
Jurisic, Iva Salatic
P0171 Intracardiac thrombus in Behçet’s disease : A report of 6
cases.
Ben Ghorbel Imed, Said Fatma, Belakhel Syrine, Ben Salem
Thouraya, Lamloum Mounir, Braham Amel, Khanfir Monia, Hamzaoui
Amira, Houman Habib
P0182 Dysregulated microRNAs related to angiogenesis
expression in endometrial cancer
Luis Andrés Ramón, Aitana Braza-Boils, Juan Gilabert-Estellés,
Juan Gilabert Aguilar, Melitina Chirivella Casanova, Francisco España
Furió, Amparo Estellés Cortés
P0192 Efficacy and safety of Fondaparinux in the treatment
of pulmonary embolism provoked by Romiplostin: a case
report
Dimitriy Arioli, Emanuele Negri, Alessia Tieghi, Annamaria Casali,
Maria Cristina Leone, Francesca Pileri, Francesco Merli, Ido Iori
P0199 LMWH and micronized progesterone in the prevention of
repeated obstetric complications in patients with multiple
pregnancy and thrombophilia.
Viktoriya Bitsadze, Natalya Makatsariya, Dzhamilya Khizroeva
P0202 Validation of a Point-of-Care INR Coagulometer in Intensive
Care Patients not on Oral Anticoagulant Therapy
Bo Joergensen, Karoline Dalgaard, Toke Ravn, Kurt Krogh Knudsen
P0203 Simple and rapid method for detection and quenching of
DXAI effects
Hans-Jürgen Kolde, Ute Lange, Elke Bucha
P0207 Factor V Leiden G1691 to A mutation is a prevalent genetic
thrombotic risk factor for recurrent pregnancy loss in
Tunisian patients
Raida Karray-Bradai, Khemais Benhaj, Haykel Trabelsi, Mourad
Chaari, Mohamed Guermazi, Choumous Kallel
P0211 Activation and balance of coagulation in pregnant
women treated with low-molecular weight heparin,
administered in therapeutic or preventive dosage
Barbara Krevel, Mojca Bozic, Sasa Smid, Matija Kozak
P0217 Long-term managing thromboprophylaxis in women with
risk pregnancy
Rumjana Apostolovska, Ivanka Nikoloska, Violeta Dejanova,
Violeta Neceva, Tatjana Makarovska-Bojadzieva
P0218 Sticky platelet syndrome in a patient with transitory
ischemic attack and her kindreds - case report.
Daniela Chuda, Peter Chudy, Lenka Bartosova, Ingrid Skornova, Jan
Stasko, Peter Kubisz
P0221 RISK FACTORS OF THROMBOSIS IN PATIENTS WITH MAY-THURNER
SYNDROME – CASE REPORTS
Lenka Bartosova, Ivana Plamenova, Daniela Chuda, Jan Stasko,
Peter Kubisz
P0222 Therapeutic angiogenesis for critical limb ischemia downregulates platelet reactivity.
Peter Chudy, Jan Hudecek, Daniela Chuda, Lubos Hlinka, Renata
Talapkova, Jan Stasko, Peter Kubisz
P0223 Biermer disease revealed by cerebral venous thrombosis.
Djameleddine Benkali, Malika Boucelma, Dalila Zemmour, Nabila
Hamzaoui, Samia Lassouaoui, Nacer Ouadahi, Abdelkrim Berrah
P0226 Monitoring of hemostasis by thromboelastometry in
normal pregnancy
Lukas Duraj, Juraj Sokol, Radoslava Simonova, Jan Stasko, Lenka
Bartosova, Peter Chudý, Miroslav Hasko, Peter Kubisz
P0230 Oral contraceptives and thrombophilia.
Jan Stasko, Lenka Bartosova, Peter Chudy, Daniela Chuda, Juraj
Sokol, Zuzana Jedinakova, Lukas Duraj, Peter Kubisz
P0237 ExACT – Extended anticoagulation treatment for VTE: a
randomised trial
Gail Heritage, Ellen Murray, Jayne Tullett, David Fitzmaurice
P0252 The levels of endothelin-1 in the plasma of patients with
peripheral vitreoretinal degeneration
Svetlana Serebrennikova, Yuri Vitkovsky
P0254 The Effects of Hemolysis and Primary Tube Under-filling
on Several Hemostasis Assays; Automatic Detection by
the Sysmex CS-2100i* System
Jacob de Haan, Joanne McGrath, Eman Ali, Avis Charlton, Hugh
Hoogendoorn
P0268 Higher risk of Idiopathic small for gestational age
newborns in Italian women carrying the Annexin A5 M2
haplotype.
Giovanni, Luca Tiscia, Donatella Colaizzo, Giovanni Favuzzi, Giovanna
D’Andrea, Patrizia Vergura, Rossana Santacroce, Maurizio Margaglione,
Elvira Grandone
P0272 Novel role of toll-like receptor 3 in tissue factor
activation through erk1/2 pathway in a murine model of
hypoxia
Indranil Biswas, Iti Garg, Bandana Singh, Gausal Khan
P0282 Thrombophilia and placental/chorion abruption in
multiple pregnancy after IVF
Victoriya Bitsadze, Nataliya Makatsariya, Olga Panfilova,
Dzhamilya Khizroeva
P0285 RISK FACTORS FOR TE RECURRENCE AFTER ORAL CONTRACEPTIVE
ASSOCIATED THROMBOEMBOLISM.
Dionysia Theocharidou, Emmanouil Papadakis, Konstantinos
Tsepanis, Anastasia Banti, Anna Karagianni, Vaia Papageorgiou, Vassilios
Papadopoulos, Vassiliki Pissanidou, Elissavet Georgiou, Anna Kioumi
P0291 ANALYSIS OF ABO GROUP IN WOMEN WITH RECURRENT
SPONTANEOUS ABORTIONS
Aránzazu García Raso, Carolina Miranda, Elham Askari, Rosa Vidal,
Raquel Mata, Pilar Llamas
P0293 Observational sTudy on antiThrombotic prevention in
thrombophILIA and pregnancy loss. The OTTILIA study
Michela Villani, Elvira Grandone, Valerio De Stefano, Walter
Ageno, Luigi Falasca, Paolo Puggina, Andrea Luigi Tranquilli, Maurizio
Margaglione
P0345 Obstetric outcomes and thrombotic risk in women
approaching ART procedures: a prospective cohort study.
Michela Villani, Giovanni, Luca Tiscia, Francesco Dentali, Donatella
Colaizzo, Filomena Cappucci, Lucia Fischetti, Walter Ageno, Maurizio
Margaglione, Elvira Grandone
P0351 In vitro response of thrombin generation (CAT) and fibrin
formation (ROTEM) with enoxaparin, dabigatran and
rivaroxaban
Samama Michel Meyer, Guinet Céline, Le Flem Lena
P0303 Immunohistochemical evaluation of the placental tissue
in women with thrombophilia and miscarriage
Ekaterina Kornyushina, Marina Zainulina, Irina Kostyuchek,
Elena Vashukova
P0360 Clinical value of thrombophilia diagnostics in women
with repeated IVF failure
Dzhamilya Khizroeva, Viktoriya Bitsadze, Natalya Makatsariya,
Nadezhda Stuleva
P0311 Association between patent foramen ovale and
cryptogenic ischemic stroke in patients 55 years old or
older
Accassat Sandrine, Quenet Sara, Comtet Claude, Epinat Magali,
Varvat Jérôme, Mismetti Patrick, Garnier Pierre
P0364 Long Term Treatment with Nadroparin During Pregnancy
and Postpartum Bone
Mineral Density
Gorana Mitic, Aleksandra Novakov Mikic, Jovanka Novakovic Paro,
Dragana Popov, Sladjana Novakovic Anucin, Visnja Canak, Sanja Gnip,
Dragan Spasic, Branka Kovacev Zavisic
P0312 Electronic alerts improve adherence and adequacy of
VTE prophylaxis in a tertiary care hospital from Cordoba,
Argentina
Aldo Hugo Tabares, Guadalupe Caballero Escuti,, María Teresita
Cornavaca, Francisco Bernabeu, María Eugenia Garzón Oliva, Ana
Soledad Vergottini, Romina Ivana Benkovic, Ricardo Arturo Albertini
P0365 Mortality clinical predictor factors in the pulmonary
embolism patients
Mireia Feliu Masgoret, Francesc Marimon Cortés, Alexander
Córdoba Castro, Patricia Sahún Gómez, Jordi Merino Ribas, Sandra
Parra Pérez, Raimon Ferré Vallès, Antoni Castro Salomó
P0314 The progress ways in the improvement of IVF results based
on revealing hemostasis pathology and its correction
Andrey Momot, Inna Lydina, Ludmila Tsyvkina, Galina Serduk,
Oksana Borisova
P0378 TIME IN THERAPEUTIC RANGE AND COMPLICATIONS OF
ANTITHROMBOTIC TREATMENT
Pavica Radovic, Jelena Kovacev, Sladjana Novakovic-Anucin, Sanja
Gnip, Visnja Canak, Gorana Mitic
P0319 Decreased Threshold of Aggregation to Low-Dose
Epinephrine is Evidence of “Platelet Hyperaggregability” in
Patients with Thrombosis
Chelsea Hayes, Sumire Kitahara, Oxana Tcherniantchouk
P0379 Several polymorphisms in the ADAMTS13 gene in a patient
with thrombotic thrombocytopenic purpura (TTP)
Julio Cesar Calderazzo, Ana Catalina Kempfer, Juvenal Paiva,
Analia Sanchez-Luceros, Adriana Inés Woods, María Angela Lazzari
P0324 Can the previous therapeutic control of the main risk
factors to cerebrovascular disease influence the
acetylsalicylic acid-non responsive status in acute
ischemic stroke patients?
Margarida Freitas-Silva, Luciana Gonçalves, Rui Medeiros, Jose
Pedro Nunes
P0387 Thrombophilia in systemic lupus erythematosus: a casecontrol study
Smiti Khanfir Monia, Belfeki Nabil, Hamzaoui Amira, Ben Salem
Thouraya, Mahjoub Sonia, Keddous Asma, Ben Romdhane Neila,
P0326 The prevalence of congenital and acquired thrombophilia
and hyperhomocysteinemia in women with repeated in
vitro fertilization failure.
Marina Zaynulina, Marina Mirashvili
P0327 Thromboembolism prophylaxis after cesarean section
(PRO-CS) Trial
Farjah Algahtani, Hessa Al Dohami, Saud Abo-Harbesh, Abdel Galil
Abdel Gader, Aamer Aleem
P0330 Optimizing centrifugation conditions for preparing
Platelet Concentrates
Mojgan Pourmokhtar, Ebadollah Salek Moghaddam, Fatemeh
Abbasi, Soudabeh Banazadeh
P0331 ADAMTS-13 and the platelets activity of the
microcoagulation of the blood at the PAI-1 polyporfism.
Maria Matveeva, Ekaterina Shelest, Ludmila Popova, Lev Patrushev,
Igor Bokarev
P0334 Influence of a contraceptive vaginal ring delivering
Etonogestrel and Ethinyl Estradiol and a combined
oral contraceptive containing Ethinyl Estradiol and
Dezogestrel on coagulation and platelet activation.
Veronika Shmeleva, Ludmila Papayan, Natalia Aganezova
P0339 An automated antithrombin antigen assay on
Instrumentation Laboratory ACL TOP analyser
Peter Cooper, Kieron Hickey, Fiona Coath, Mike Makris
P0340 An automated progressive assay of antithrombin
Peter Cooper, Kieron Hickey, Fiona Coath, Mike Makris
P0394 STROKE IN SICKLE CELL ANEMIA: A Case Report
Yurdanur Kilinç, Barbaros Şahin Karagün, Esra Pekoak, İlgen
Şaşmaz
P0403 Prevalence of FV Leiden, prothrombin FII 20210G>A, PAI-1
(SERPINE1) 4G/5G, GPVI 13254T>C, SERPINC1 ( IVS +141G>A) and
CYP4V2 Lys259Gln in Czech Republic.
Jan Kvasnicka, Jaroslava Hajkova, Petra Bobcikova, Tomas
Kvasnicka, Daniela Duskova, Zdenek Krska
P0417 How we manage antithrombotic treatment in pregnancy
high risk thrombotic situations:
Beatriz E Grand, Maria Monica Gonzalez Alcantara, Geraldine Voto,
Liliana S Voto
P0420 EFFECTIVE OUTCOME OF PREGNANCIES IN CASES OF RECURRENT
FETAL LOSSES
A. Foifa, MP. Makris, PE. Makris
P0421 Pregnancy outcomes in women with inherited bleeding
disorders (IBD) in a public hospital:
Beatriz E Grand, Maria Monica Gonzalez Alcantara, Guadalupe
Madrid, Geraldine Voto, Liliana S Voto
Join the MLTD!
Visit our booth and discover the advantages
to be member of the MLTD
The society aims to create bridges between clinical practice and basic
science, bringing together research scientists on vascular and molecular
biology and clinicians of many different disciplines such as Hematology,
Cardiology, Neurology, Angiology, Surgery, Internal Medicine, Gynecology
and other disciplines related to Thrombosis, currently the main cause of
mortality in the western world.
The Society contributes to the translation of scientific advances to clinical
practice with a multidisciplinary and international approach, organizing
international congresses on Thrombosis, Educational Courses and Symposia
oriented to the advance in the fight against Thrombosis.
- Discounted rates for Members in the biannual International
Congresses on Thrombosis and other scientific activities that
the MLTD will organize.
- Online subscription to our official Journal, Thrombosis
Research
- To be nominated and to receive Society and Congress Awards
www.medleague-thrombosis.org
MLTD General Secretary
Mª Teresa Santos Ph. D.
Research Center. University Hospital "La Fe"
Avda Campanar, 2146009 Valencia (SPAIN)
santos_ter@gva.es
GRUPO GEYSECO
MLTD Technical Secretariat
Universidad, 4 46003 Valencia (SPAIN)
tel. (+34) 963 524 889 fax. (+34) 963 942 558
mltd@geyseco.es
{
Changing landscape in anticoagulation
– new perspectives and treatment strategies
Satellite Symposium
The 22nd International Congress
on Thrombosis (ICT)
Sunday, 7 October 2012 12:45-13:45
‘Hermes’ room, Acropolis, Nice, France
Lunch will be provided
12:45 WELCOME & INTRODUCTION
Chair: Professor Patrick Mismetti, Saint-Etienne, France
12:50 NOVEL ANTICOAGULANTS – NEW
PERSPECTIVES IN ATRIAL FIBRILLATION
Professor José Luis Zamorano, Madrid, Spain
13:05 CURRENT LANDSCAPE OF VENOUS
THROMBOEMBOLISM – THE CLINICIAN’S VIEW
Professor Patrick Mismetti, Saint-Etienne, France
13:25 NEW DIRECTIONS IN VENOUS
THROMBOEMBOLISM MANAGEMENT
Professor Walter Ageno, Varese, Italy
13:35 PANEL DISCUSSION & MEETING CLOSE
All
www.epicea.com - Photo : Shutterstock - ©2011 Diagnostica Stago - All rights reserved - Non-contractual photos - 09/2012
Generate Performance
Stago, worldwide reference in Haemostasis
• Integrated solutions, well known for their reliability (analysers, reagents, consumables)
• Innovations designed to facilitate the daily laboratory practice
• Extensive range of tests for both routine and research settings
• Performance-boosting services and environment (interconnectivity, technical
assistance, diagnostic and accreditation support, EQA, training, logistics, etc.)
• Recognised by the international scientific community for its expertise
• Global network ensuring fast, local service in over 110 countries
Diagnostica Stago S.A.S
RCS Nanterre B305 151 409
9, rue des Frères Chausson
92600 Asnières sur Seine (France)
Ph. +33 (0)1 46 88 20 20
Fax +33 (0)1 47 91 08 91
webmaster@stago.com
www.stago.com
Venue Plan
AUDITORIUM ATHÉNA
ROOM GALLIENI 5
16
COMMERCIAL EXHIBITION
POSTERS ZONE
A
B C
RHODES ROOM
PREVIEW ROOM
AUDITORIUM HERMÉS
ENTRANCE
TECHNICAL
SECRETARIAT
03
01
11- 12
04
13-14
05
16
A
INFORMATION DESK
B
MLTD
C
BUSINESS CENTER
07-08
18
09-10
19
Sponsor Profiles
BAYER HEALTHCARE
Contact: Olivier Morboeuf
Medical adviser
E-mail:olivier.morboeuf@bayer.com
Mobile: + 33 6 21 02 46 79
Bayer HealthCare is among the world’s foremost innovators in the field of pharmaceutical and medical products. This subgroup’s mission is to
research, develop, manufacture and market innovative products that improve the health of people and animals throughout the world.
The globally operating Health Care subgroup is divided into four operating divisions: The goals of the Animal Health Division are to maintain the
health of animals and cure veterinary diseases, with the focus primarily on treating infectious diseases and repelling parasites. The main focus
of the Consumer Care Division is on non-prescription medicines and dietary supplements. One example is Aspirin, a more than 110-year-old
brand that enjoys an unsurpassed level of global familiarity. Medical Care comprises the businesses with blood glucose monitoring devices and
medical equipment for diagnosis and treatment.
The Pharmaceuticals Division is today the highest-selling pharmaceuticals company in Germany and holds a worldwide leading position in its
main therapeutic areas. The focus is on prescription medicines. The division combines its strengths in two business units: General Medicine
and Specialty Medicine.
BOEHRINGER-INGELHEIM
www.boehringer-ingelheim.com
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates
globally with 145 affiliates and more than 44,000 employees. Since it was founded in 1885, the family-owned company has been committed to
researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine.
As a central element of its culture, Boehringer Ingelheim pledges to act socially responsible. Involvement in social projects, caring for employees
and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and
respect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim’s endeavors.
In 2011, Boehringer Ingelheim achieved net sales of about 13.2 billion euro. R&D expenditure in the business area Prescription Medicines corresponds to 23.5% of its net sales.
DAIICHI-SANKYO
The Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging markets. The company was created in 2005 through the merger of two traditional Japanese
enterprises, Daiichi and Sankyo. With net sales of more than €8.6 billion, Daiichi Sankyo is one of the world’s 20 leading pharmaceutical companies. The company’s world headquarters are in Tokyo. Its European base is located in Munich. Daiichi Sankyo Europe has affiliates in 12 European
countries in addition to a global manufacturing site located in Pfaffenhofen, Germany.
DSM
Contact: Mr. Michael Janssen
The Branch Pentapharm, since 2007 part of DSM, is a manufacturer of haemeostasis diagnostics:
Test kits e.g. Pefakit® APC-R Factor V Leiden, PiCT® (for UFH, LMWH and/or anti-FIIa and FXa drug monitoring), Reptilase Time, in-TDT® (for
thrombin generation), or OEM products.
Reagents (from research to bulk quantities) including customer manufacturing n: synthetic chromogenic, fluorogenic and amperogenic substrates, protease inhibitors and snake venom enzymes.
Active pharmaceutical ingredients: aprotinin, peptides and snake venom derived enzymes (Batroxobin, Haemocoagulase ) and synthesis of
peptides and small organic molecules.
INTRUMENTATION LABORATORY
Instrumentation Laboratory (IL) is passionate about delivering the most innovative solutions to address a range of hemostasis testing needs.
The advanced ACL™ family of systems brings complete automation to the hemostasis lab—including the ACL TOP® Family of Hemostasis Testing Systems, featuring the new ACL TOP 300 CTS; and, the ACL AcuStar®, the first fully automated, chemiluminescent analyzer for hemostasis
specialty testing. Combined with the HemosIL line of reagents, a comprehensive panel of fully automated assays, IL offers complete disease
state management for the hemostasis lab.
LEO PHARMA
www.leo-pharma.com
www.leo-pharma.fr
Founded in 1908, LEO Pharma is an independent, research-based pharmaceutical company based in Ballerup near Copenhagen. LEO Pharma is
wholly owned by the LEO Foundation. LEO Pharma develops, manufactures and markets competitive drugs for thrombosis patients and in dermatology in more than 100 countries. LEO Pharma has offices in 61 countries and employs more than 5000 employees worldwide.
LFB GROUP
The LFB group is a biopharmaceutical company that develops, manufactures and markets medicinal products for serious and often rare diseases,
in three major therapeutic areas: immunology, hemostasis and intensive care.
Leader in France and 6th player worldwide in the field of plasma-derived medicinal products, the LFB Group also is a leading European company
in the development of monoclonal antibodies and new generation proteins derived from biotechnologies.
With its strong research activities, the LFB group is developing a growth strategy to expand its business activities by offering new therapeutic
treatments and expanding into new international markets.
ROCHE
www.roche.com
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and
CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche’s
personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of
life and survival of patients. In 2011, Roche had over 80,000 employees worldwide and invested over 8 billion Swiss francs in R&D. The Group
posted sales of 42.5 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake
in Chugai Pharmaceutical, Japan.
ROVI
Address: Julian Camarillo, 35
28037 Madrid (Spain)
Telephone: 913756230 Fax: 913047881
E-mail: rovi@rovi.es
www.rovi.es
ROVI is a fully-integrated, profitable Spanish specialty pharmaceutical company engaged in the research, development, in-licensing, manufacturing and marketing of small molecule and specialty biologic drugs. The Company has a diversified portfolio of products that it markets in Spain
through its specialized sales force, calling on specialist physicians, hospitals and pharmacies. ROVI’s portfolio of 30 principal marketed products
is currently anchored by the internally-developed, second generation low molecular weight heparin, Bemiparin which is also out-licensed and
marketed in 50 countries thanks to a network of partners. ROVI’s research and development pipeline is focused primarily on addressing currently
unmet medical needs by developing new Bemiparin indications and the novel ISM (“in-situ microparticles”) technology for injectable forms.
SIEMENS
Siemens Healthcare Diagnostics Products GmbH
Contact: Michael Nöh
Vice President BU HHS Global Marketing
Address: Emil-von-Behring-Straße 76
35041 Marburg (Germany)
E-mail: michael.noeh@siemens.com
www.siemens.com/healthcare
Siemens Healthcare Diagnostics offers a comprehensive portfolio of performance-driven systems, unmatched test menu, and information technology solutions for the in vitro diagnostic needs of hospital labs, reference labs, physician office labs, and point-of-care testing. We provide
clinicians with the vital information they need for accurate diagnosis, treatment, and monitoring of patients. Our diagnostic solutions — chemistry, immunoassay, automation, hematology, hemostasis, microbiology, diabetes, urinalysis, blood gas, and molecular testing — are designed
to streamline workflow, enhance operational efficiency, and support improved patient care.
STAGO
Stago dedicates its research and innovative skills to develop and improve the accuracy of the medical diagnostic. The firm formulates, manufactures and markets worldwide, a broad range of reagents and fully automated systems for Haemostasis & Thrombosis.
Thanks to its Haemostasis expertise, Stago is recognized and is in a position to cooperate with the scientific community worldwide.
Sponsors
GOLD SPONSOR
SILVER SPONSOR
BRONZE SPONSOR
SPONSORS
OFFICIAL JOURNAL
MEDIA PARTNER
5
VOLUME 130, ISSUE 4
OCTOBER 2012
ISSN 0049-3848
THROMBOSIS
RESEARCH
THROMBOSIS RESEARCH
Anti-Xa
range
VOLUME 130, ISSUE 4, PAGES 571–692
www.epicea.com - Photo : Eric Meola/Gettyimages - ©2011 Diagnostica Stago - All right reserved - No contractual photos - 01/2012
130
4
Connecting the World of
Biomedical Science
STA®-Liquid Anti-Xa
OCTOBER 2012
The solution for UFH, LMWH and
Fondaparinux monitoring
Liquid format, easy to use and reproducible
Medical and Scientific Publishers
Fully automated assay
Wide working range and increased on-board stability
Dedicated and hybrid calibrations available
ELSEVIER
Diagnostica Stago S.A.S
RCS Nanterre B305 151 409
9, rue des Frères Chausson
92600 Asnières sur Seine (France)
Ph. +33 (0)1 46 88 20 20
Fax +33 (0)1 47 91 08 91
webmaster@stago.com
www.stago.com
Available online at www.sciencedirect.com
TECHNICAL SECRETARIAT
Tel.: +34 96 352 48 89
Fax: +34 96 394 25 58
www.geyseco.es

final programme

Transcription

Similar documents

Platelet count by village

A celebration of acting monologues and duets!

ben roethlisberger - Seneca Valley School District

Spontaneous Thrombosis and Subsequent Recanalization

Los Lonely Boys Luma Theater - School Of The Arts (CSU Chico)

ARE YOU A BEN 10 BRAIN BOX?

Chapter 21 Fetal Thrombotic Vasculopathy

Cerebral Vein Thrombosis - The Association of Physicians of India

Fine Arts Center School Arts Brochure

Holy Land Experience

rackham auditorium - University of Michigan